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A STUDY ON BACTERIAL INFECTIONS AND THEIR ANTIMICROBIAL 
SUSCEPTIBILITY PATTERN IN DECOMPENSATED LIVER DISEASE PATIENTS 
IN A TERTIARY CARE HOSPITAL                                  
ABSTRACT 
 
INTRODUCTION: Bacterial infections in decompensated liver disease (DCLD) patients are 
one of the most frequent complications and result in high mortality and morbidity. Patients 
with DCLD have altered and impaired immunity, which favours bacterial infections. The 
most common infection in DCLD patients are spontaneous bacterial peritonitis followed by 
urinary tract infections, Spontaneous bacteraemia, pneumonia, and skin and soft-tissue 
infections. The prognosis of these patients is closely related to a prompt and accurate 
diagnosis and appropriate treatment decreases the mortality rates.  
Aim & objective: This study was done to determine the various bacterial agents causing 
infections in decompensated liver disease patients and to determine the drug susceptibility 
and resistance pattern and to identify their associated risk factors (HBV, HCV)  and to 
estimate the level of C3 component of complement in DCLD patients by ELISA. This study 
was conducted at the Institute of Microbiology, Madras Medical College, Chennai 
 Materials &Methods: About 150 patients (≥18 yrs), admitted in various wards of our 
hospital with signs & symptoms suggestive of bacterial infections in DCLD patients are 
included in the study. Ascitic fluid, urine, sputum and wound swab were collected. Blood and 
serum samples were collected from all the patients and processed according to Standard 
Microbiological techniques. Detection of HBsAg, Anti HCV ELISA was done according to 
the manufacturer guidelines to find out the associated risk factors for DCLD and to correlate 
the bacterial infections with complement C3 level by ELISA. 
Results: A total of 150 DCLD patients, from September 2013 to August 2014, were 
included. The common age group involved was 41-60 years, being 97% male. The alcoholic 
etiology of DCLD was 84%. Out of 150 samples, culture positivity seen in 54% (81/150).In 
81 culture positive isolates, 63(78%) were Gram Negative bacilli and 18 (22%) were Gram 
Positive cocci, which was correlated significantly [P value = 0.005]. Among 81 culture 
positive cases, The most common infection in DCLD patients are spontaneous bacterial 
peritonitis[27%] followed by urinary tract infections[26%], Spontaneous bacteraemia[19%], 
pneumonia[16%], and skin and soft-tissue infections[12%]. Among Gram negative bacilli, 
Escherichia coli were the most common isolates and in Gram positive cocci, Staphylococcus 
aureus was the most common isolates.  
Most of the organisms were 75% sensitive to amino glycosides and 50% sensitive to 
fluoroquinolones. All the GNB were 100% sensitive to carbapenem except one carbapenem 
resistant isolates, Klebsiella oxytoca was isolated from sputum sample.  
  In 81 culture-positive infections, 33[41%] drug resistant bacterial infections were identified: 
27 ESBL (81%), 4 Methicillin resistant Staphylococcus aureus (10%) 1 VRE (2.3%), and 1 
MBL(2.3%). Of the culture-positive infections, these drug resistant bacterial infections 
occurred in 11 of 21 (52%) of the UTIs, 8 of 22 (36%) of the SBP, 3 of 15 (20%) of the 
spontaneous bacteraemia cases, 7 of 13 (54%) of the pneumonia and 4 of 10 (40%) of the 
skin and soft tissue infection cases. 
In our study, the prevalence of Hepatitis B surface antigen and Anti hepatitis C virus by 
serological methods (ELISA) were found to be 8%  and  7.3% respectively. 
Out of 150 total samples, Complement component C3 ELISA was done for randomly 
selected 88 samples with one kit due to economic constrains. Out of 88 patients, 59(67%) 
patients with low complement component C3 level. Of which 35(59%) patients were culture 
positive and 24(41%) were culture negative. 29(33%) with normal complement component 
C3 level, of which 25(86%) were culture negative and 4(14%) were culture positive. 
Discussion: In our study, males were commonly involved in DCLD patients due to presence 
of risk factors like alcoholism. The main causes of DCLD were alcoholic liver diseases. The 
commonest age group which showed most of the bacterial infections was between 41-50 age 
groups. The most common and serious bacterial infections in DCLD patients were 
Spontaneous bacterial peritonitis than other infections. Gram negative bacilli were common 
isolates than Gram positive cocci. In Gram negative bacilli, E.coli was the main pathogen. 
High rate of antibiotic resistant isolates were seen in culture-positive infections, with 41% (33 
of 81cases). Bacterial infections were associated with low complement component C3 level 
in DCLD patients. 
Conclusion: The prognosis of these patients is closely related to identify the definitive 
etiologic diagnosis with its antimicrobial susceptibility and resistant pattern. Antibiotic 
prophylaxis must be restricted to selected patients and encouraging the use of first line 
antibiotics and to avoid unnecessary use of higher antibiotics like third generation 
cephalosporins will help to reduces the occurrence of new resistant strains, which can be 
significantly reduce hospital stay and morbidity and improve survival rate. 
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INTRODUCTION 
Liver failure leading to cirrhosis is one of the most common causes of 
death in our country 
[1, 2]
. Cirrhosis is a chronic progressive liver disorder 
caused by alcoholic liver diseases, viral hepatitis (HBV and HCV) and 
cryptogenic causes 
[3]
 which can leads to liver failure and death 
[4]
.   
According to the stages of liver injury, signs and symptoms and survival 
rate, cirrhosis is classified into Compensated and Decompensated liver 
diseases 
[5]
. 
Decompensated liver disease (DCLD) is defined as irreversible chronic 
injury of the hepatic parenchyma and extensive fibrosis in association with the 
formation of regenerative nodules and leading to loss of liver function 
[6]
. 
DCLD is associated with one or more of the complications like ascites, portal 
hypertension, gastro esophageal hemorrhage and hepatic encephalopathy  
Bacterial infections are more common in decompensated liver disease 
patients and causes 30%-50% of deaths in these patients. 
[7]
.  Spontaneous 
bacterial peritonitis, the (SBP) is a serious  bacterial infection in 
decompensated liver disease patients  followed by urinary tract infections 
(UTI), spontaneous bacteraemia, pneumonia, and skin infections 
[8]
. The 
common causative organisms for bacterial infections in DCLD patients are 
Enterobacteriaceae,  nonfermentable gram-negative bacilli and Gram positive 
cocci and most of them are multidrug resistant 
[9-10]
.  
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In DCLD patients with bacterial infections, 40% are nosocomial and\ 
60% are community acquired infections 
[13]
. Even though the incidence of 
bacterial infections in cirrhosis is not high but the mortality rate is very high.                              
Bacterial infections in decompensated liver disease are due to invasive practical 
procedures, malnutrition 
[15]
, derangement of gut flora – intestinal stasis, 
bacterial over growth, increased intestinal permeability, impaired host defence 
mechanisms against infection.  
Of the host defence mechanisms, impaired function of the 
reticuloendothelial system 
[16]
, deficiency of complement component level 
mainly C3 because C3 is synthesized by hepatocytes of liver and impaired 
opsonisation activity increases the susceptibility of infections in DCLD 
patients. Low concentrations of C3 in serum as well as low concentrations of 
C3 in ascetic fluid predispose to spontaneous bacterial peritonitis 
[17]
. 
This study was done to determine the various bacterial agents causing 
infections in decompensated liver disease patients and to identify their 
associated risk factors and to determine the drug susceptibility and resistance 
pattern. Early identification of the source of bacterial infections in 
decompensated liver disease patients and appropriate antibiotic treatment will 
reduce morbidity and mortality. 
                                         
                     
3 
 
AIM AND OBJECTIVES 
1. To study the etiological agents causing bacterial infection in DCLD 
patients. 
2. To determine the antimicrobial susceptibility pattern of the isolated 
pathogens by Disc diffusion method and Minimum inhibitory 
concentration by Broth dilution method. 
3. 3. To find out the incidence of HBsAg and  Anti HCV positivity    in 
DCLD patients by Enzyme linked immuno sorbent assay. 
4. To estimate the level of C3 component of complement in DCLD 
patients by Enzyme linked immunosorbent assay. 
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REVIEW OF LITERATURE 
The name “Cirrhosis” was given by Laennec in 1826 [19], derived from 
the Greek word “kirrhos” means yellowish tan colour [20]. The first theory for 
pathogenesis of cirrhosis was advanced by Roessle in 1930. 
Liver is the largest gland in the body and liver tissue contains two main 
cell types: Kupffer cells and Hepatocytes.
[147] 
Kupffer cells are a type of macrophage that capture and break down old, 
worn out red blood cells passing through the sinusoids. 
Hepatocytes are cuboidal epithelial cells that line the sinusoids and 
make up the majority of cells in the liver. Hepatocytes perform most of the 
liver’s functions – metabolism, storage, digestion, and bile production [21].   The 
liver has many complex functions. 
NORMAL MICROFLORA OF VARIOUS PARTS OF GASTRO 
INTESTINAL TRACT (GIT) 
[118]
:   
Normally, the stomach contains 10
3 
colony forming units (CFU) of 
microorganisms / ml 
[42]
. Mainly it contains facultative Gram positive salivary 
microorganisms such as Lactobacilli, aerobic Streptococci and Candida 
species.  The organisms will be numerous in achlorhydria state of the stomach 
[e.g.: proton pump inhibitor users] or presence of blood in the stomach. 
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The flora from mouth to second part of the duodenum is very scanty 
mainly consists of salivary microorganisms. The organisms of the normal flora 
will be high during achlorhydria or intestinal obstruction.  The distal part of 
ileum and the large intestine normally contains Escherichia coli, Enterococci 
and obligate anaerobes such as Bacterioides fragilis and Bifidobacterium 
species. The   number of anaerobic organisms will be 10
3
 to 10
4
 times higher 
than Escherichia coli 
[28]
. Other colonic bacteria are Streptococcus viridans, 
other anaerobic Streptococci, Clostridium perfringens and Enterobacter 
species. This flora will be stable and may be altered by antibiotic therapy. 
Stability of normal flora is maintained by number of factors such as gut 
motility, local pH, mucosal binding sites and production of antibacterial 
substances from luminal organisms 
[37]
.
 
 
During perforation of intestine, initially a total of > 10
11 
organisms enter 
into peritoneal cavity. Among which only 3 to 4 types of organisms only are 
responsible for peritoneal infection. Bacterioides fragilis is the obligate 
anaerobe most commonly isolated after colonic perforation. 
Defence mechanism 
The liver functions as an organ of the immune system through the 
function of the Kupffer cells that line the sinusoids.  
 Kupffer cells are a type of fixed macrophage that form part of the 
mononuclear phagocyte system along with macrophages in the spleen 
and lymph nodes. 
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 Kupffer cells play an important role by capturing and digesting bacteria, 
fungi, parasites, worn-out blood cells, and cellular debris. 
 Kupffer cells secrete many complements.  
 The large volume of blood passing through the hepatic portal system 
and the liver allows Kupffer cells to clean large volumes of blood very 
quickly. 
Cirrhosis of the liver 
The World Health Organization (WHO) definition for Cirrhosis is 
defined as: “irreversible diffuse process characterized by fibrosis and the 
conversion of normal liver architectures into structurally abnormal nodules” [22] 
and leading to loss of liver function 
[24].
 
Epidemiology: 
Cirrhosis is the tenth leading cause of death for men and the twelfth for 
women in the United States in 2001, killing about 27,000 people each year 
[23]
. 
The estimated prevalence of cirrhosis around the world is 100per 100 000 
subjects. Many patient die due to cirrhosis in the fifth or sixth decade of the 
life. In 2002, according to the 2003 World Health Organization report, 783000 
individuals died from cirrhosis. In the USA in 1998 a prevalence of more than 
5.5 million cases of Chronic liver disease or cirrhosis was estimated, with a rate 
of 2030 cases per 100000 populations. The mortality rate was approximately 
25000 deaths. The 10-year survival rate for compensated liver diseases is 
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nearly 90%, while the median survival after decompensation is about 2 years 
[24]
 
Patho physiology of cirrhosis
:[2]
 
Pathogenesis of cirrhosis is complex. Death of hepatocytes, extracellular 
matrix deposition, and vascular reorganization are the central pathogenic 
processes in cirrhosis. The liver cells are injured by a chronic disease process, 
which then undergo inflammatory changes leading to cell death (necrosis) and 
fibrosis.  
Etiology for cirrhosis: 
The common causes of Cirrhosis in India are  
Alcoholic liver diseases - 60 to 70% 
Viral hepatitis - 10% 
Cryptogenic diseases - 10 to 15% 
Biliary diseases - 5 to 10% 
Primary Hemochromotosis - 5% 
Wilson’s disease - Rare 
Alpha 1 antitrypsin deficiency - Rare 
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Alcoholic liver disease : 
Alcohol related liver disease is very common global problem. World 
Health Organization (WHO) estimates that 140 million people worldwide 
suffer from alcohol dependency, causing liver damage. Classification of liver 
damage due to alcohol consumption  
 Alcohol fatty change (steatosis) - It may be reversible if the 
patients stop the consumption of alcohol. 
 Acute alcoholic hepatitis- Due to consumption of large amount of 
alcohol for a long period. It may cause abnormal liver functions 
without any symptoms of liver failure. 
 Cirrhosis- Alcohol causes significant liver damage; normal liver 
cells are replaced by fibrosis and nodules. 
 End- stage Alcoholic liver disease- Death occurs due to profuse 
gastrointestinal bleeding, hepatic encephalopathy, overwhelming 
bacterial infections, renal failure and hepatocellular carcinoma. 
Japan and India were previously of low prevalence, but now alcoholic 
cirrhosis is gradually on the rise  in India 
[25]   
. 
Acetaldehyde, metabolic end product of Alcohol,  is a reactive molecule 
and it may interact with proteins and membrane lipids, causing alterations in 
their structure and function, which may lead to cell injury and cell death 
[2]. 
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Concomitant alcohol abuse and hepatitis C virus occur in about 14% of 
individuals with chronic liver disease. Alcohol and HCV act simultaneously to 
increases the incidence of cirrhosis 
[26, 27].
At least 80% of heavy alcohol 
drinkers developed steatosis, 10% - 35% develop alcoholic hepatitis and 10% 
will develop cirrhosis 
[28]
. 
Cirrhosis due to Viral hepatitis  
Cirrhosis mainly caused by Hepatitis B and Hepatitis C viruses. 
Hepatitis B is a major health problem in India. India is at the intermediate 
endemic level of hepatitis B carrier, based on the hepatitis B surface antigen 
(HBsAg).  In India over 40 million (4 crore) populations are HBsAg carriers. 
These chronically infected people are at high risk of death from cirrhosis 
[29]
. 
Worldwide, about 170 million individuals are infected with HCV, of which 
[30]
80% develop chronic hepatitis C, and of those 20- 30% will develop 
cirrhosis over 20- 30years 
[3]. 
Cryptogenic cirrhosis: 
Cryptogenic cirrhosis is defined as any cirrhosis for which the etiology 
is unknown                     
Classification of cirrhosis of liver 
 According to the size of the nodules: 
1. Micro nodular cirrhosis- Nodules less than 3mm in size, uniform 
and encompass one lobule. 
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2. Macro nodular cirrhosis- Nodules more than 3mm, vary in size 
and encompass more than one lobule. 
3. Mixed [31, 32]. 
According to the histological features: Portal, Post-necrotic, Post 
Hepatitis, Biliary, and Congestive. 
According to the etiologic agents: Genetic, Toxic, Infectious, Biliary, 
Vascular, Cryptogenic 
[32]
. 
         According to the clinical presentation:  
 Compensated liver diseases. 
 Decompensated liver diseases. 
About one third of cirrhosis are compensated type  and do not produce 
any clinical symptoms and may be discovered at a routine examination or 
biochemical screen or at operation theatre for some other condition
[33]
 but  the 
liver still has the ability to function normally or compensate for the damage 
[24].
  
Decompensated liver diseases are an irreversible alteration of the liver 
architecture, consisting of hepatic fibrosis and areas of nodular regeneration
 [31]
. 
Clinical features of Cirrhosis: 
The following signs and symptoms may occur in the cirrhosis or due to 
the complication of cirrhosis.  
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 Jaundice 
 Splenomegaly 
 Visible distended veins over the abdomen 
 Caput medusae 
 Gynaecomastia 
 Hypogonadism 
 Spider angiomatis or Spider navi [34] 
  Clubbing 
  Dupuytren’s contracture 
 Fetor hepaticus 
 Pedal edema due to hypo albuminaemia 
 Other symptoms are weakness, fatigue, anorexia, weight loss (35). 
Complication of the Decompensated liver diseases: Decompensated liver 
diseases are complicated by the following features 
 Ascites 
 Portal hypertension        
 Gastroesophageal haemorrhage:  
 Hepatic encephalopathy  
 Malnutrition  
 Abnormalities in coagulation. 
 Bone disease  
 Hematologic abnormality 
12 
 
Bacterial infections in Decompensated liver disease: 
 Bacterial infection is a severe complication of decompensated cirrhosis 
which is accounts for both longer hospital stay and increased mortality 
[18]
. 
Puneeta Tandon et al
 [36]
 and Foreman MG et al
 [37]
 reported that once bacterial 
infections occur, it may lead to sepsis and death in DCLD patients
.
  
Bacterial infections is usually asymptomatic in patients with 
decompensated liver disease, Clinical suspicion of infection must be high as the 
only indication may be a general deterioration in the patient’s clinical state, 
increasing encephalopathy or renal impairment 
[38, 39]. 
 
Borzio M et al reported in 2001 that the bacterial infections occur in 32 
to 34% of hospitalized patients with cirrhosis 
[18, 40]
 of which 45% were 
admitted with gastrointestinal hemorrhage 
[41]
, and is responsible for 30%-50% 
of deaths 
[7] 
Mathurin S et al reported in 2009 that the mean age was 51.8 (+/-8) 
years, and 84.8% were male. The alcoholic etiology of cirrhosis was 95.4% 
[13].
 
The most common infections in decompensated liver disease patients 
are spontaneous bacterial peritonitis (32.7%) 
[42]
, followed by urinary tract 
infection (31.8%) and pneumonia (15.9%) 
[43, 44]
. The most frequent causative 
organisms are Gram-negative bacilli, mainly Escherichia coli (60%). 
Spontaneous bacterial peritonitis or primary bacterial peritonitis  
Spontaneous bacterial peritonitis (SBP) is defined as an abrupt onset of 
acute bacterial peritonitis without an apparent intra-abdominal source of 
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infection in patients with ascites and decompensated liver disease
 [45]
. This is a 
frequent and severe complication of cirrhosis, with an incidence in hospitalized 
patients with cirrhosis of 7%-25%. Decompensated liver disease patients with 
low ascitic fluid (AF) protein, elevated serum bilirubin levels, low platelets  
and low complement component C3 level in serum and ascetic fluid, diagnostic 
and therapeutic paracentesis are the important risk factors for developing  
spontaneous bacterial peritonitis (SBP) 
[47, 48].
 
The vast majority of Spontaneous bacterial peritonitis (SBP) patients are 
presented with abdominal pain and fever followed by vomiting, hepatic 
encephalopathy, gastrointestinal bleeding.  
The most frequently identified organisms in patients with Spontaneous 
bacterial peritonitis (SBP) are Gram-negative bacilli mainly Escherichia coli 
and Gram-positive cocci mainly Enterococci.  
Clinical features and presenting symptoms for patients with Cirrhotic 
abdomen and tuberculous abdomen are very much similar, but the 
characteristics of the ascitic fluid are different, which are enumerated in the 
following 
[52] 
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Differentiation of tuberculous peritonitis from spontaneous bacterial 
peritonitis: 
[53] 
SAAG - Serum-Ascites Albumin Gradient,  ADA - Adenosine Deaminase. 
TLC- Total Leukocyte Count 
 Urinary tract infections: Urinary tract infections (UTI) in 
decompensated liver disease patients are the second most common infection 
Characteristics 
Ascitic  fluid from 
Cirrhotic peritonitis 
Specific gravity 
SG<1016 
Ascitic fluid from 
Tubercular Peritonitis 
SG>1016 
Protein <2.5g/dl >2.5g/dl 
SAAG >1.1 <1.1 
Leukocyte count 
TLC < 500, [normal] 
Predominantly 
mesothelial cells. 
TLC >500 predominantly 
lymphocytes 
ADA <40 >40 
PCR for 
Mycobacterium 
tuberculosis 
Negative Positive 
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next to spontaneous bacterial peritonitis. These patients are frequently 
presented with asymptomatic bacteriuria 
[55, 56]
. The incidence of urinary tract 
infections is higher in DCLD patients, due to immunocompromised state and 
indwelling urinary catheters. The most frequent bacteria isolated from urinary 
tract infections are Escherichia coli and Klebsiella pneumoniae. 
Pneumonia: Pneumonia is the third most common infection in 
decompensated liver disease patients, after spontaneous bacterial peritonitis 
and urinary tract infections, especially those with alcoholism, hepatic 
encephalopathy, gross ascites and management of oesophageal varices with 
balloon tamponade are predisposing factors.
 [57]
. The commonly isolated 
organisms are Gram negative bacilli (K. pneumonia), Streptococcus 
pneumoniae, Haemophilus influenzae and Mycoplasma pneumonia 
[58, 59]
. 
Skin and soft-tissue infections: Edema of the lower extremities and 
anterior abdominal wall which can be due to reduced albumin level and gross 
ascites are predisposed to skin infections in decompensated liver disease 
patients. The most common organisms causing skin infections are 
Enterobacteriaceae, Staphylococcus aureus and Streptococcus pyogenes, 
followed by anaerobes 
[60-62]
. 
Spontaneous bacteraemia: The Porto systemic shunt circulation in 
DCLD patients will favour the organisms to escape from phagocytosis by 
hepatic reticuloendothelial system, there by establishing systemic bacteraemia. 
Prognosis very poor in patients with bacteraemia and decompensated liver 
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diseases.
[49, 54]
. This blood stream infection is caused by Gram negative bacteria 
followed by Gram positive cocci.  Escherichia coli are the frequently isolated 
organism followed by Pseudomonas aeruginosa 
[63]
 Klebsiella pneumoniae, 
Enterobacter cloacae, Citrobacter freundii and Enterobacter aerogenes. 
Risk factors for Bacterial infection in Decompensated liver disease: 
 Invasive practical procedures.  
 Malnutrition. 
 Derangement of gut flora – intestinal stasis, bacterial over 
growth. 
 Increased intestinal permeability. 
 Impaired host defence mechanisms against infection. 
Invasive practical procedures: 
Insertions of intravenous or urethral catheter, diagnostic and therapeutic 
paracentesis, Endoscopy are highly predisposed to development of bacterial 
infections in decompensated cirrhotic patients. Of which 4 to 20% of 
bacteraemia may be caused by Intravenous catheter 
[64
. Patients who require 
esophageal tamponade for bleeding varices are prone to develop aspiration 
pneumonia 
[65]. 
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Malnutrition  
Liver is mainly involved in energy and protein metabolism in our body. 
There are many factors involved in malnutrition of cirrhosis, including poor 
dietary intake, alterations in gut nutrient absorption, and alterations in protein 
metabolism. 
Derangement of gut flora  
 The bacteria that are responsible for the infections are derived from the 
normal flora of the gastrointestinal tract [GIT] 
(66)
. Increased intestinal bacterial 
over growth is due to altered intestinal motility and prolonged intestinal transit 
[67]
. 
Decreased intestinal IgA or bile salts can favour intestinal bacterial over 
growth in cirrhosis which is the main mechanism for bacterial translocation 
(68, 
69). 
Translocation of bacteria from the gut to extra intestinal sites is one of 
the mechanisms for bacterial infections in DCLD patients.  Bacterial 
translocation of a specific organism is always associated with intestinal 
bacterial over growth of the same organism. Gram negative enteric bacteria 
translocation more frequently than Gram positive organisms 
[70].
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Increased intestinal permeability:
[71]
 
The alterations in the structures of gastrointestinal tract by congestion of 
vascular system, oedema of the intestine, intracellular space widened and 
inflammation of the peritoneum in DCLD patients may predispose to an 
increase in intestinal permeability.  
Impaired host defence mechanism 
Immune dysfunction in the cirrhotic patients is multi factorial 
[72, 73]
. 
Impaired function of the reticuloendothelial system, deficiency of complement 
component level mainly C3, impaired opsonisation activity also decrease in 
bactericidal activity 
[74, 75 & 76]
 have been implicated in the pathogenesis of the 
increased susceptibility to infections of patients with cirrhosis. 
 The phagocytic function of the reticuloendothelial cells are reduced due 
to intra hepatic shunting of blood in cirrhotic patients 
[77, 78]
. The reduced serum 
concentration of complement and fibronectin play an important role in the 
decreased action of reticuloendothelial system (RES) 
[79]
.  
   Kupffer cell is the main component of monocyte macrophage system.  
Impaired Kupffer cell function in cirrhosis liver leads to significantly reduced 
phagocytic activity and bactericidal activity 
[60]
.  
 Acquired deficiency of certain complement components especially C3 in 
serum occur because Complement component C3 is mainly synthesized from 
hepatocytes of liver and its concentration in ascitic fluid is significantly 
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reduced in patients with advanced cirrhosis 
[80]
. Complement component 3 is 
one of the important prognostic factors to assess the severity of cirrhosis 
[17]
.  
The following mechanisms contribute to low level of serum complement in  
DCLD  patients 
1. Some complement component are directly synthesized by hepatic 
parenchymal cells and their synthesis may be reduced as a direct 
consequence of injury and death of hepatic parenchymal cells 
[81]
  
2. Extra hepatic   synthesis of other complement components are also 
reduced due to metabolic disturbance associated with liver failure 
[82]
. 
3. There may be circulating in activators for complement components are 
also present. 
4. There may be increased consumption of complement by antigen- 
antibody complex 
[83]
. 
5. Increased catabolism or increased loss of complement component into 
the urinary or  gastrointestinal tract.  
The concentration of the third component of complement (C3) in ascitic 
fluid and serum appears to have the best predictive value for bacterial 
infections 
[84]
. 
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MULTIRESISTANT BACTERIAL INFECTIONS IN DCLD 
There is a increased prevalence of bacterial infections in DCLD patients, 
due to multiresistant bacteria (pathogens resistant to the main antibiotics, 
including β-lactams). The most common are extended-spectrum β-lactamase–
producing Enterobacteriaceae, nonfermentable gram-negative bacilli (e.g., 
Pseudomonas aeruginosa), methicillin-resistant Staphylococcus aureus 
(MRSA), vancomycin-susceptible Enterococci (VSE), and vancomycin-
resistant Enterococcus (VRE). Epidemiological patterns of multi resistance are 
different among geographical areas. Multi resistant bacteria are more 
frequently isolated in nosocomial infections (35%-39%) compared with HCA 
(14%-20%) or community-acquired episodes (0%-4%). Type of multi resistant 
bacteria also varies among infections. Risk factors for multi resistant bacterial 
infection include current or recent hospitalization, health care support, and 
previous exposition to β-lactams or fluoroquinolones, including long-term 
Norfloxacin prophylaxis.  
LABORATORY DIAGNOSIS OF BACTERIAL INFECTIONS IN DCLD 
Early diagnosis and treatment of bacterial infection is pivotal in the 
management of patients with decompensated cirrhosis and is based on history, 
clinical examination and laboratory diagnosis.  
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Basic investigations: 
1. Complete haemogram. 
2. Biochemical test - Blood sugar, 
Blood urea and Serum creatinine 
3. Liver function test – Total bilirubin, Direct Bilirubin 
Total protein, Albumin and Globulin 
AST, ALT 
Serum alkaline phosphatase 
Gamma glutamyl transferase 
4. Renal function test 
5. Serum iron and hepatic iron to rule out Hemochromotosis. 
6. Anti smooth muscle antibody and anti LKM antibody- to rule out Auto 
immune hepatitis. 
7. Anti mitochondrial antibody to rule out Primary biliary cirrhosis. 
8. KF ring by slit lamp examination, serum and urinary content of copper 
to rule out Wilson’s disease. 
9. Serum α feto protein to rule out malignancy. 
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10. Ascitic fluid paracentasis: Cell count and biochemical test. If ascetic 
fluid neutrophil count more 500cell/µl diagnosis of spontaneous 
bacterial peritonitis. 
11. Leukocyte Esterase Reagent Strip used for spot diagnosis of 
spontaneous bacterial peritonitis 
Other investigations: 
 Ultrasono gram 
 Computed tomogram 
 Liver biopsy – To rule out liver cell size and presence of nodule with 
fibrosis septa 
 Radio- isotope scan – To rule out the stages of cirrhosis. 
Serological investigations 
 Antigen and antibody detection for hepatitis B virus 
 Antibody detection for hepatitis C virus 
 Detection of complement component level 
Bacteriological investigations 
1. Ascetic fluid culture and antibiotic sensitivity 
2. Blood culture and antibiotic sensitivity 
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3. Sputum culture and antibiotic sensitivity 
4. Urine culture and antibiotic sensitivity 
5. Wound swab culture and antibiotic sensitivity. 
Specimens include ascitic fluid, blood, sputum, urine and wound swab. 
Direct gram stain followed by culture and the organisms are identified by 
standard microbiological techniques and antibiotic sensitivity as per CLSI 
guidelines. 
DETECTION OF RESISTANCE IN GRAM NEGATIVE BACILLI: 
A) Extended spectrum beta lactamase (ESBL) 
[85,86]
: 
These are Bush class A plasmid mediated beta lactamase capable of 
hydrolyzing Penicillin and monobactams and inhibited by beta lactamase 
inhibitors but have no detectable activity against cephamycins or carbapenems 
and is produced mainly by members of family Enterobacteriaceae, and also by 
some non fermentors. They also carry resistance for other group of antibiotics 
(like amino glycosides, fluoroquinolones, cotrimoxazole etc) which  narrow  
down the choices of antibiotics available for  treatment. 
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Detection methods for Extended Spectrum Beta Lactamase 
:[87]
 
1. Screening methods: with cefotxime / Ceftriaxone / cefpodoxime / 
ceftazidime /aztreonam discs by disc diffusion method 
2. CLSI phenotypic confirmatory methods:  broth micro dilution 
method/disc diffusion method. 
3. Other methods: Inhibitor potentiated disc diffusion test, double disc 
diffusion Synergy test, ESBL Epsilometer test, automated methods. 
4. Molecular methods: PCR, DNA probes, PCR-RFLP, PCR-SSCP, 
Oligonucleotide sequencing. 
b) AMPC PRODUCTION IN GRAM NEGATIVE BACILLI: 
Amp C beta lactamase are Bush class C beta lactamase (plasmid or 
chromosomal mediated), which   are resistant to all beta lactamase and also to 
beta lactamase inhibitor combinations. They are sensitive to 4th generation 
cephalosporin and to carbapenems. The main Amp C producing microbes were 
Acinetobacter species and Klebsiella species. 
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Detection methods AmpC beta lactamase :[88,89] 
1. Screening methods:  cefoxitin disc by disc diffusion method, Cefoxitin 
agar method, inhibitor based methods, AmpC disc test, modified three 
dimensional test, Amp C beta lactamase  Epsilometer  test. 
2. Molecular methods: PCR based methods 
C) Metallo beta lactamase in gram negative bacilli :[90, 91] 
These are Bush class C beta lactamase capable of hydrolyzing 
carbapenems, other beta lactams and beta lactamase inhibitors with the 
exception of aztreonam. They are predominantly found in Acinetobacter 
baumanii and Pseudomonas aeruginosa. 
Detection methods for MBL : 
1. Screening methods: carbapenems disc (imipenam, meropenam, 
ertapenam etc) diffusion method. 
2. Confirmatory methods: Imipenam –EDTA combined disc method, 
Imipenam EDTA double disc synergy test (DDST),EDTA disc 
potentiation test, HODGE test, MBL Epsilometer test 
3. Molecular methods: PCR techniques 
26 
 
ANTIMICROBIAL RESISTANCE IN STAPHYLOCOCCUS AUREUS:  
Penicillin resistance: 
[92]
 
Penicillin resistance has been increasingly recognized since 1945.Nearly 
80% or more strains of Staphylococcus aureus are resistant to penicillin. It is of 
3 types 
Plasmid mediated resistance: It is due to the production of the enzyme 
penicillinase (beta lactamase mediated by plasmids. The enzyme inactivates 
penicillin by splitting the beta lactam rings. Staphylococcus aureus produce 4 
types of penicillinase (A, B, C, D).These plasmids are transmitted to 
Staphylococci by transduction and conjugation. The plasmid also carry 
resistance to other antibiotics like erythromycin and fusidic acid. 
2. Chromosomal mediated resistance: 
Reduction in the affinity of penicillin binding protein on the cell wall 
also plays a role in mediating resistance to penicillin and other beta lactam 
antibiotics. 
3. Tolerance to penicillin: 
Staphylococci developing tolerance to penicillin are only inhibited but 
not killed. 
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METHICILLIN RESISTANCE: 
Methicillin resistance Staphylococcus aureus (MRSA) are resistant to 
penicillin and beta lactam antibiotics. Resistant to Methicillin indicates 
resistance to all cephalosporins. Many MRSA isolates are resistant to other 
antimicrobial families, including amino glycosides, quinolones and macrolides.  
The prevalence of MRSA has shown an increasing trend in India.In 
1996,  Pulimood from Vellore reported 24%[124].The following year Udaya 
Shankar from Pondicherry reported 20%.In 2006 Rajaduraipandi reported 
37.9% from Coimbatore.[94-96]A study conducted by INSAR group ,showed 
that the prevalence of MRSA in our country is about 40 %.[97] 
Mechanism of resistance 
Mediated by mecA gene which encodes for penicillin binding protein2a 
(PBP2a) that has low affinity for beta lactams. mecA is carried on a mobile 
genetic element the Staphylococcal cassette chromosome (SCCmec). Five 
types of SCCmec have been reported. 
 Type I, II, III- HA-MRSA 
 Type IV a-d and V, Panton Valentine leukocidin (PVL)- with sub 
units  lukS-PV  and  lukF PV-CA-MRSA 
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 Other mechanisms of  methicillin resistance:-  
Some strains of Staphylococcus aureus are not intrinsically resistant to 
methicillin and lack mecA and PBP2a. 
BORSA (Border line Resistant Staphylococcus aureus) are less 
susceptible to methicillin because of hyper production of normal penicillinase.  
MODSA (Methicillin Intermediate Staphylococcus aureus show 
methicillin resistance due to their mechanisms and have normal PBP. Both 
these groups are genetically distinct from MRSA and of unknown clinical and 
epidemiological importance though their infections can be effectively treated 
with beta lactamase resistant penicillin and cephalosporins.  
Detection and identification  of MRSA: 
MRSA can be detected by both phenotypic and genotypic methods; The 
ideal method for identification is by detection of mecA gene or its product 
PBP2a. But because of the high cost and requirement of expertise it is not 
performed in most clinical laboratories and phenotypic identification of 
intrinsic methicillin resistance is the standard method followed. A strain of 
Staphylococcus aureus is considered resistant to methicillin if the minimum 
inhibitory concentration (MIC) of oxacillin is≥4µg/ml [139]. Oxacillin is 
preferred as it is more stable than methicillin. 
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Methods of identification of MRSA:[98] 
1. Screening methods: with cefoxitin/oxacillin disc by disc diffusion 
method 
2. Confirmatory methods: Oxacillin MIC detection (by broth dilution, agar                                                       
dilution, E test method), Oxacillin screen agar. 
3. Molecular methods: detection of mecA gene or PBP2aprotein (its 
protein product) 
Other methods are[99,100]  
 MRSA screen Latex tests, 
 Evigene MRSA kit Chromogenic agar 
 MRSA Select (Bipo-rad) 
 Chrome Agar MRSA (Bio connections). 
Typing methods for MRSA: 
1.Biotyping: 
 It is a method to characterize  MRSA based on biochemical and 
morphological properties.
[101]
.Based on the following 4 properties 
 Tween 80 hydrolysis 
 Pigment production on Tween 80 agar 
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 Urease production 
 Gentamicin resistance 
Based on the result MRSA isolates have been divided into 4 
groups(A,B,C.D) 
In India Biotyping by this technique was done for the first time in 1993 
by Krishna Prakash S and showed that majority belongs to group B. He 
reported the same finding a decade later also. Similar finding were found by 
other author’s also [102,103].Since this technique is easy to perform, inexpensive 
and reproducible, in can be incorporated as a daily bench top procedure. 
Antibiogram: MRSA can also be typed based on the susceptibility to a 
range of antibiotics. It is easy to perform but has a poor discriminatory ability 
and lacks reproducibility. 
2. Genotypic methods:[104,105] 
 Plasmid analysis 
 Chromosomal DNA 
 Restriction enzyme analysis 
 Southern hybridization 
 Ribotyping 
 Coagulase gene typing 
 Protein A gene typing 
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 RAPD 
 Rep-PCR 
 Mec-A:Tn 554 probe typing 
 Pulse- field gel electrophoresis 
RESISTANCE TO OTHER ANTIBIOTICS: 
Erythromycin and Clindamycin: 
These two are two different classes of antimicrobial agents the inhibit 
protein synthesis by binding to 50S ribosomal unit of bacterial cell. In 
Staphylococci resistant to both these drugs occur through methylation of their 
ribosomal target site. Such resistance is mediated by the msrA. Another 
mechanism of resistance is by inactivation of lincosamides by chemical 
modification, which is mediated by inuA gene. 
The target site modification mechanism also called macrolide 
lincosamide-streptograminB (MLSB) resistance results in resistance to 
erythromycin, clindamycin and streptograminB.This may be constitutive or 
inducible. In constitutive rRNA methylase is always produced, whereas in 
inducible methylase is produced only in the presence of an inducer. 
Invitro, Staphylococcus aureus isolates with constitutive resistance are 
resistant to Erythromycin and clindamycin and isolates with inducible 
resistance are resistant to erythromycin but appear susceptible to clindamycin 
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and in vivo therapy with clindamycin may select for erm mutants , and leads to 
clinical failure. 
Invitro induction test can distinguish inducible erm –mediated resistance 
from those with msr-A mediated resistance. This is known as D-test.[106] 
Fluoroquinolones:  
Pefloxacin, ciprofloxacin and ofloxacin have activity against 
Staphylococcus and can be considered for treatment.  The target of 
Fluoroquinolones in Staphylococci is topoisomerase IV DNA gyrase.A point 
mutation in the grl A gene ,that encodes the A subunit of topoisomerase IV 
leads to resistance. Thus the major limitation of Fluoroquinolones is that 
resistance develops easily and hence have a limited role as monotherapy in 
serious infections
.[107].
 
Amino glycosides: Gentamicin, netilmycin and tobramycin are the most 
effective amino glycosides against Staphylococci. But not effective as a 
monotherapy due to emergence of resistance. Plasmid mediated resistance 
develops against Gentamicin
.[107,108
] 
Vancomycin and Teicoplanin: These are glycopeptides active against 
MSSA and MRSA. Mi – Na Kim et al 2000 reported a case of Vancomycin 
intermediate resistance in Staphylococcus aureus in Korea 
Mupirocin: It is a pseudomonic acid, a natural product of Pseudomonas 
fluorescens. It acts by inhibiting isoleucyl-tRNA synthetase in Staphylococci. It 
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is used topically to eradicate nasal carriage .Resistance develops due to the 
presence of an isoleucyl-tRNA synthetase gene located on a conjugative 
plasmid encoding Gentamicin resistance
.[108] 
ANTIBIOTIC TREATMENT FOR BACTERIAL INFECTIONS IN 
DCLD
[109] 
                          
1. ESBL-producing Enterobacteriaceae- Carbapenems 
2. MRSA and VSE – Glycopeptides or Linezolid 
3. Uncomplicated urinary tract infections- Nitrofurantoin 
4. Pseudomonas aeruginosa - Meropenam or Ceftazidime and 
Ciprofloxacin                  
  Prevention of Infection in Cirrhosis: Antibiotic prophylaxis must be 
restricted to selected patients at a very high risk for the development of 
bacterial infections. This restriction of antibiotic usage to prevent the 
development of antibiotic resistance in DCLD patients and to make these 
prophylactic strategies cost-effective. Current indications of antibiotic 
prophylaxis in DCLD are gastrointestinal bleeding, low protein ascites, and 
previous episode of SBP 
[110-1
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MATERIALS AND METHODS 
Place of study:  
The study was conducted in the Institute of Microbiology, Madras 
Medical College in association with various other Departments (Internal 
Medicine, Gastroenterology, and Hepatology etc) Rajiv Gandhi Government 
General Hospital (RGGGH), Chennai. Informed consent was obtained from the 
study population. All patients satisfying the inclusion criteria were included in 
this study. 
STUDY DESIGN AND STUDY PERIOD: 
The study design was cross sectional study.The study period was from 
September 2013 to August 2014 (one year).  
Study group:  
A total of 150 patients of Decompensated Liver disease (DCLD) 
admitted in various wards of RGGGH with complaints suggestive of bacterial 
infections like high grade fever, cough with sputum production, altered 
sensorium, dyspnoea, burning micturition   were taken for the study.  
ETHICS CONSIDERATION: 
This study was conducted after the required approval from the 
Institutional Ethics Committee. Informed consent was obtained from the study 
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population. All patients satisfying inclusion criteria  were included in this 
study. Patients were interviewed by a structured questionnaire. 
Inclusion criteria: 
 Patients of more than 18 years age. 
 Patients with Decompensated liver diseases admitted in various wards 
with signs and symptoms suggestive of bacterial infections. 
Exclusion criteria: 
 Patients of less than 18 years age. 
 Patients with other causes of  peritonitis (Tuberculous peritonitis, 
Malignant ascites) 
Collection of data: 
Data were collected from patients who satisfied the inclusion criteria, 
using preformed structured questionnaire. Demographic details like name, age, 
address, date of admission, diagnosis at admission, habitual history [smoking, 
alcoholism], past and present Medical history, physical examination findings, 
nutritional status, underlying illness (Diabetes mellitus, Tuberculosis, 
malignancy, immunosuppressive drugs Uraemia,)  were also included. 
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Sample collection and Transport: 
Under strict aseptic precautions, samples were collected in sterile 
containers, properly labeled and were transported to the laboratory in 
appropriate conditions and processed as early as possible.  
Types of Samples collected: 
1. Ascitic fluid. 
2. Blood sample. 
3. Urine. 
4. Sputum 
5. Wound swab 
PROCEDURE OF SAMPLE COLLECTION, TRANSPORTATION AND 
PROCESSING: 
COLLECTION OF ASCITIC FLUID / PERITONEAL FLUID: 
Under strict aseptic precautions, about 15-20 ml of free fluid in the 
abdomen (Peritoneal fluid, Ascitic fluid) was aspirated by paracentesis 
[abdominal tapping]   under ultrasound guidance from the patients. Of which 
10 ml of ascitic fluid was inoculated in to 50ml of Brain heart infusion broth at 
the bed side 
[103,104] 
and 5 ml of aspirated fluid sent to the pathology department 
for the estimation of leukocyte count 
[114]
. 
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COLLECTION OF BLOOD: 
Two sets of blood samples (20 ml) were drawn over a 24hr 
period
113]
.Using a pressure cuff, suitable vein was located in the arm. Deflate 
the cuff while disinfecting the venepuncture site. Venepuncture site disinfected 
with 70% alcohol and then with 2% povidone iodine. The disinfecting agent 
was allowed to act for 1 minute and then 20 ml of blood was drawn through a 
sterile syringe, 10 ml was added aseptically into 50 ml of Brain heart infusion 
broth 
[113,115-116]
. 
Collection of sputum sample 
[116]
: 
Just before the collection of sputum sample, the patients were advised to 
rinse their mouth with water. The patients were requested to take deep breath in 
and exhale several times and then collected deeply coughed sputum in a clean, 
dry, wide-necked, leak proof, screw-capped container. 
Collection of urine: 
Patients were instructed to collect clean catch midstream urine sample in 
a screw capped wide mouthed sterile container. In case of patients with 
indwelling catheter, under aseptic precaution sample was collected from 
sampling port .The sample was immediately transported to the laboratory. 
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Collection of wound swab: 
The wound with surface exudates was washed with sterile saline or 70% 
alcohol. Tissue or aspirates   were preferred over wound swab specimen. The 
swabs were passed deep into the base of the lesion to firmly sample the fresh 
border. Two swabs were collected, one for Gram staining and the other for 
culture. 
Specimen processing: 
Ascitic fluid 
5 – 10 ml of aspirated ascitic and peritoneal fluid observed for 
macroscopic characteristic features of fluid (color, turbidity, purulent, blood 
stained).Then, the peritoneal/ascitic fluid was centrifuged at 1500rpm for 10 
minutes. The sediment was used for further processing. 
Sputum 
[117-118]
: 
Sputum sample was homogenized by vortexing and processed further. 
All the sputum samples were prescreened with Gram’s stain, using Bartlett 
scoring system 
[119]
. 
Urine: 
A loopful of well mixed uncentrifuged urine was placed on a clean glass 
slide and allowed to air dry, then heat fixed, Gram staining was carried out and 
examined under oil immersion (X100) field of light microscope and the 
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number of pus cells, epithelial cells and bacteria was recorded (1 pus cell per 
low power field corresponds to 3 cell per µl).  
A loopful of uncentrifuged urine samples was plated onto blood agar 
and MacConkey agar. The plates were incubated at 37°C for 24 hours. The 
number of colonies grown counted and interpretated as colony forming unit per 
ml (CFU/ml) of urine by multiplying the number of colonies grown by 100. 
Colony counts exceeding , 10
5
 CFU/ml is suggestive of significant bacteriuria 
DIRECT MICROSCOPY 
All the samples like ascitic fluid, blood, sputum, urine and wound swab 
were subjected for Gram’s staining. 
Gram’s stain – to detect the presence of bacteria, pus cells, their Gram 
reaction, morphology and their arrangement. 
CULTURE 
All the samples were inoculated onto the following  culture media by 
using calibrated loop of 0.01ml and incubated under specified condition  
 Nutrient Agar at 37°C incubated for 24 hours. 
 5 % sheep Blood agar in 5-10% CO2 at 37°C incubated for 24 hours 
 Chocolate agar in 5-10% CO2 at 37°C incubated for 24 hours. 
 MacConkey agar at 37° incubated for 24 hours. 
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   INTERPRETATION: 
Interpretation of bacterial cultures: 
[120]
 
Bacterial isolates were identified by means of colony morphology, Gram 
staining, motility, Catalase, oxidase, Coagulase and other biochemical reactions 
as per standard recommended Microbiological techniques. 
ANTIMICROBIAL SENSITIVITY  TESTING: 
Antibiotic susceptibility testing was performed to know the sensitivity 
and resistant pattern of all the isolates by the Kirby Bauer method on Cation 
Adjusted Mueller Hinton agar (Himedia) according to CLSI guidelines 
[121]
. 
The diameter of zones of inhibition was interpreted according to CLSI 
standards for each organism. Media and discs were tested for quality control 
using ATCC strains. 
The following standard ATCC strains were used 
 Escherichia coli-ATCC 25922 
 Staphylococcus aureus- ATCC 25923 
 Pseudomonas aeruginosa –ATCC 27853 
 Klebsiella pneumonia(ESBL) –ATCC 700603 
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The panel of antibiotics included in the antimicrobial sensitivity testing for 
Gram negative bacilli were (Himedia). 
 
Antibiotics Disc content 
Inhibition zone in mm 
Resistance Intermediate Sensitive 
Amikacin 30µg 14 15-16 17 
Ceftazidime 30µg 14 15-17 18 
Cefotaxime 30µg 14 15-17 18 
Ciprofloxacin 5µg 15 16-20 21 
Ofloxacin 5µg 12 13-15 16 
Gentamicin 10µg 12 13-14 15 
Imipenem 10 µg 13 14-15 16 
Piperacillin/ 
Tazobactum 
100/10µg 17 18-20 21 
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The panel of antibiotics included in the antimicrobial sensitivity testing for 
Gram positive cocci were (Himedia), 
 
Antibiotics Disc content 
Inhibition zone in mm 
Resistance Intermediate Sensitive 
Amikacin 30µg 14 15-16 17 
Ciprofloxacin 5µg 15 16-20 21 
Cotrimoxazole 1.25/23.75µg 10 11-15 16 
Chloramphenicol 30µg 12 13-17 18 
Clindamycin 2µg 14 15-20 21 
Penicillin 10units 28 - 29 
Rifampicin 5µg 16 17-19 20 
Erythromycin 15µg 13 14-22 23 
Cefoxitin 30µg 21 - 22 
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Antimicrobial susceptibility testing by Kirby – Bauer Disc Diffusion 
method:
[119]
 
 Taken 3 to 5 identical colonies from agar plate culture by using sterile 
bacteriological loop, and transferred into normal saline. 
 The colony suspension was matched with 0.5McFarland standard 
turbidity. 
 A sterile non – toxic, non-absorbable cotton swab was dipped into the 
inoculum. 
 Streaking the swab 3 times over the Cation Adjusted Mueller Hinton 
agar (CAMHA) plate surface, rotating the plate approximately 60 
degrees to confirm an equal distribution. Replaced the lid of the dish and 
allowed 3 to 5 minutes. 
 Approximately five antimicrobial discs were placed on the surface of 
90mm diameter plate with the help of forceps and incubated at 37
0
C 
overnight. 
 After incubation, zone of inhibition was measured in mm from the edge 
of the disc to the zone edge. 
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DETECTION OF ß LACTAMASE ENZYME PRODUCTION IN GRAM 
NEGATIVE BACILLI: 
EXTENDED SPECTRUM ß- LACTAMASES (ESBL) DETECTION 
METHODS: 
ESBL’s are classified under Bush class A ß- lactamase which are 
capable of hydrolyzing penicillin – oxyiminocephalosporins and monobactams 
(Aztreonam) and inhibited by ß-lactamase inhibitors (clavulanic acid, 
sulbactum and tazobactum) but have no detectable activity against 
cephamycins or carbapenems (Imipenem, Meropenem). 
ESBL Screening method: 
[122, 123]
 
Isolates of gram negative bacilli showing the following resistance 
pattern were considered to be possible ESBL producing strains. 
Antibiotic Zone diameter for possible ESBL 
producing strain 
Ceftazidime(30µg) ≤ 22mm 
Cefotaxime(30µg) ≤ 27mm 
Ceftriaxone(30µg) ≤ 25mm 
Aztreonam(30µg) ≤ 27mm 
Cefpodoxime(10 µg) ≤ 17mm 
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 For Proteus mirabilis:  Cefpodoxime≤ 22mm  
     Ceftazidime   ≤ 22mm  
     Cefotaxime    ≤ 27mm  
Double Disk Diffusion Synergy Test: 
[124]
 
The third generation cephalosporin disc and Augmentin disc 
[Amoxicilin and Clavulanic acid] (20µg/10µg) (Himedia) were kept 30mm 
apart from centre to centre on Cation Adjusted Mueller Hinton agar (MHA). A 
clear extension of the edge of the inhibition zone of cephalosporin towards 
Augmentin disc was interpreted as positive for ESBL production. 
Phenotypic Confirmatory Double Disk Test: (PCDDT) 
[124]
 
3 – 5 identical colonies were picked from a fresh overnight grown 
culture with   a sterile bacteriological loop and inoculated into 5 ml of normal 
saline and then turbidity matched with 0.5 McFarland’s standard. Lawn culture 
of the test organism was made on to MHA plate (Himedia, Mumbai), 
Antibiotic disc Ceftazidime (CAZ 30µg) and Ceftazidime / Clavulanic acid 
(CAZ/CA 30µg /10µg) (Himedia, Mumbai) were placed 20mm apart onto the 
plate and incubated at 35
0
 C overnight. The difference of ≥ 5mm increase in 
zone diameter for Ceftazidime tested in combination with Clavulanic acid 
versus its zone when tested alone confirmed an ESBL producing organism. 
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Detection of carbapenemase production by Modified Hodge test 
[125] 
A 0.5 McFarland dilution of the Escherichia coli ATCC 25922 in 5 ml 
of broth or normal saline was prepared. A 1:10 dilution was streaked as lawn 
on to a Cation Adjusted Mueller Hinton agar plate. A 10 µg ertapenam 
susceptibility disk was placed in the center of the test area. Test organism, 
positive control and negative control were streaked in a straight line from the 
edge of the disk to the edge of the plate. The plate was incubated overnight at 
35±2°C in ambient air for 16–24 hours.  
After 24 hrs, MHT Positive test showed a clover leaf-like indentation of 
the Escherichia coli ATCC 25922 growing along the test organism growth 
streak within the inhibition zone. MHT Negative test showed no growth of the 
Escherichia coli ATCC 25922 along the test organism growth streak within the 
disc diffusion. 
Minimum inhibitory concentration (MIC) for detecting Meropenam 
Resistance in Klebsiella oxytoca : 
1. Culture media: Cation adjusted Mueller Hinton broth (pH 7.2-7.4). 
2. Preparation of antibiotic stock solution: 
Antibiotic stock solution can be prepared using the formula, 
W =  1000  x  V  x  C 
            P 
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Where P= potency of the antibiotic in relation to the base. (For Meropenem, 
P= 675/1000 mg) 
                  V = volume of the stock solution to be prepared (10ml) 
                  C = final concentration of the antibiotic solution (1024μg/ml) 
                 W = weight of the antibiotic to be dissolved in the volume V 
15.17 mg of drug was mixed with 10ml of distilled water which contains 
1024 concentration of drug.  
3. Preparation of Antibiotic dilutions: 
 Two rows each of 14 sterile test tubes were arranged in the rack (1 row 
for the test & 2
nd
 row for ATCC control). 
 Using sterile pipette, 1ml of MH broth was transferred to all the tubes in 
the rack. 
 From the stock solution 1 ml was transferred to the first tube in each row 
and mixed well. 
 From the first tube 1 ml of the antibiotic solution was transferred to 
second tube.  
 This procedure was repeated till the 14th tube. 
 For growth control, 1 ml of inoculum in a test tube without antibiotic 
should bekept in each row. 
 The sterility control for the antibiotic solution was also kept. 
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4. Inoculum preparation for the test and ATCC control strain : 
 9.9 ml of MH broth was taken in a sterile test tube. 
 0.1ml of 0.5 McFarland turbidity matched test organism was added to 
broth and mixed well. 
 From the above inoculum 1 ml was transferred to each tube containing 
antibiotic dilutions and also to the control tube using sterile syringe. 
 Same procedure was repeated for ATCC control strain. 
5. Incubation: 
The rack was incubated at 37ºC overnight. 
 Interpretation: 
MIC of ATCC control strain and the test organism were observed. 
The lowest concentration of the antibiotic which shows clearing was 
considered as the MIC for the ATCC strain & for the test isolate. 
MIC of meropenam in Enterobacteriaceae:
(126)
 
≤ 1µg/ml –     Susceptible 
2µg/ml – Intermediate 
≥4µg/ml -   Resistant 
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DETECTION OF METHICILLIN RESISTANCE IN STAPHYLOCOCCUS  
AUREUS:
[127]
 
 Cefoxitin disc diffusion method: 
 Media  -Muellar Hinton Agar 
 Antibiotic disc  --Cefoxitin disc 30 µg 
 QC Strain  ----   Staphylococcus aureus ATCC 25923 was used 
PROCEDURE:
[119, 121]
 
5-6 similar colonies of the organism were picked up from the over night  
incubated culture plate and inoculated into 5 ml of normal saline and incubated 
at 37°C for 2 hours. Standard control strain of Staphylococcus aureus ATCC 
25923 was also inoculated into normal saline and incubated as above. The 
turbidity of the control and test strains was adjusted to 0.5 McFarland's 
standard. The test strain was swabbed all over the surface of the Muellar 
Hinton medium three times, rotating the plate through an angle of 60° after 
each application and finally, passing the swab round the edge of the agar 
surface. Similar method was followed for the control strain. A 30µg cefoxitin 
disc was applied using a sterile forceps at the center of the each plate and 
pressed gently to ensure even contact with the medium. The plates were 
incubated at 37°C and readings were taken on the next day. 
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Interpretation: As per CLSI guidelines 2013 
 Zone of inhibition-≥22mm-MSSA 
 Zone of inhibition-≤21mm-MRSA 
2. Minimum Inhibitory Concentration (MIC) for detecting Vancomycin  
resistance: 
1. Culture media: Cation adjusted Mueller Hinton broth.(pH 7.2-7.4) 
2. Preparation of stock antibiotic solution: [131] 
Antibiotic stock solution can be prepared using the formula 
W =  1000  x  V  x  C 
            P 
Where P= potency of the antibiotic in relation to the base. (For vancomycin, 
 P= 950/1000 mg; Himedia) 
V = volume of the stock solution to be prepared (10ml) 
C =final concentration of the antibiotic solution (1024μg/ml) 
W = weight of the antibiotic to be dissolved in the volume V 
Scheme of preparing dilution of antibiotics 
 Two rows each of 14 sterile test tubes were arranged in the rack (1 row 
for the test & 2
nd
 row for ATCC control). 
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 Using sterile pipette, 1ml of MH broth was transferred to all the tubes in 
the rack. 
 From the stock solution 1 ml was transferred to the first tube in each row 
and mixed well. 
 From the first tube 1 ml of the antibiotic solution was transferred to 
second tube.  
 This procedure was repeated till the 14th tube. 
 For growth control, 1 ml of inoculum in a test tube without antibiotic 
should be   kept in each row.       
 The sterility control for the antibiotic solution was also kept. 
b.  Inoculum preparation for the test and ATCC  control  
 9.9 ml of MH broth is taken in a uricol container 
 0.1ml of 0.5 McFarland turbidity matched test organism is added to 
broth 
 Mixed well and transferred 1 ml of inoculum using 2 ml syringe to each 
tube containing antibiotic dilutions and also to the control tube. 
 Same  procedure repeated for ATCC control strain 
 The rack was incubated at 37ºC for 24 hrs. 
 MIC of ATCC control strain and the test organism was observed. 
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 The lowest concentration of the antibiotic in which there is no visible 
growth is considered as the MIC for the ATCC strain & for the test 
organisms. 
Interpretation: 
MIC of vancomycin for staphylococcus aureus :
(126) 
≤ 2µg/ml –     Susceptible 
4-8µg/ml – Intermediate 
≥16µg/ml -   Resistant 
MIC of vancomycin for Enterococci : 
(127)
 
≤ 4µg/ml –     Susceptible 
8-16µg/ml – Intermediate 
≥32µg/ml -   Resistant  
SEROLOGICAL INVESTIGATIONS: 
1. Detection of Complement component C3 level by Enzyme linked                             
immunosorbent assay method 
2. Detection of Anti HCV by Enzyme linked immunosorbent assay 
method. 
3. Detection of HBsAg by Enzyme linked immunosorbent assay method. 
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DETECTION OF COMPLEMENT COMPONENT C3 LEVEL BY             
ENZYME LINKED  IMMUNOSORBENT ASSAY METHOD: 
Human Complement component C3 level was detected by Enzyme 
linked immunosorbent assay in serum by using AssayMax Human 
Complement C3 ELISA Kit manufactured by ASSAYPRO agencies. The 
technique of ELISA was performed as per the manufacturer guidelines. 
 Principle of the Assay 
The AssayMax Human Complement C3 ELISA Kit was designed for 
detection of Human Complement component 3 level in serum and plasma 
samples. This assay employs a quantitative competitive enzyme immunoassay 
technique that measures Human Complement component 3 in less than 3 hours. 
A polyclonal antibody specific for Human Complement component 3 has been 
pre coated onto micro titre plate. Complement C3 in standards and samples is 
competed with a biotinylated Complement C3 sandwiched by the immobilized 
antibody and streptovividin-peroxidase conjugate. All unbound material is then 
washed away and a peroxidase enzyme substrate is added. The colour 
development is stopped and the intensity of the colour is measured. 
Sample collection, preparation and storage: 
   Sample was collected into a serum separator tube. After clot 
formation, samples were centrifuged at 3000x g for 10 minutes and removed 
serum from the supernatant fluid. Then, the sample was diluted 1:800 into EIA 
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Diluent. The undiluted samples were stored at -20°C or below for up to 3 
months.  
Reagent preparation: 
All reagents are to be brought to room temperature before use and 
freshly dilute all reagents. 
EIA Diluent Concentrate:  EIA Diluent Concentrate was diluted with 
reagent grade water in 1:10 concentration. 
Reconstituted the 120µg of Human Complement C3standard with 4ml 
of   EIA Diluent to generate solution of 30 µg / ml and allowed the standard to 
sit for 10 minutes with gentle agitation prior to making dilutions. Prepared 
duplicate or triplicate standard point by serially diluting the standard solution 
(30 µg / ml). 1:2 with EIA diluent to produce 15, 7.5, 3.75, 1.875, 0.938 and 
0.469 µg / ml solutions. EIA diluent serves as the zero standard (0 µg / ml).Any 
remaining solution should be frozen at -20°C and used within 30 days. 
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Standard Point Dilution Complement C3level            
(µg / ml) 
P1 Standard (30 µg / ml) 30.00 
P2 1 part of P1 + 1 part of EIA 
diluents 
15.00 
P3 1 part of P2 + 1 part of EIA 
diluents 
7.500 
P4 1 part of P3 + 1 part of EIA 
diluents 
3.750 
P5 1 part of P4 + 1 part of EIA 
diluents 
1.875 
P6 1 part of P5 + 1 part of EIA 
diluents 
0.938 
P7 1 part of P6 + 1 part of EIA 
diluents 
0.469 
P8 EIA diluents 0.000 
Biotinylated Human Complement C3 (1x). Reconstituted Biotinylated 
humaComplement C3 with 4 ml EIA Diluent to produce a working solution. 
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Assay Procedure 
1. Added 25 µl of human complement C3 standard or sample per well and 
immediately added 25 µl of biotinylated human complement C3 to each 
well and mixed gently. Covered wells with a sealing tape and incubated 
for 2 hours. 
2. Washed 5 times with 200 µl of  wash buffer manually and hit 4 to 5 
times on absorbent material to completely remove the liquid. 
3. Added 50 µl of Streptavidin Peroxidase conjugate to each well and 
incubated for 30 minutes and wash 5 times with 200 µl of wash buffer 
manually. 
4. Added 50 µl of Chromogen Substrate per well and incubated for about 
20 minutes or until the optimal blue colour density develops. 
5. Added 50 µl of stop solution to each well. The Colour changed from 
blue to yellow.  
6. Immediately reading was taken at a wave length of 450 nm on a micro 
plate reader. 
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Standard Curve 
For generation of a standard curve, plot the graph using the standard 
concentrations on the X axis and the corresponding mean 450 nm absorbance 
on the Y axis. 
The unknown sample concentration from the standard curve and 
multiply the value by the dilution factor was determined. 
  Reference value: 
Normal human complement C3 levels range from 0.4 to 2 mg/ml. 
DETECTION OF ANTI HCV BY ENZYME LINKED IMMUNOSORBENT 
ASSAY: 
The third generation HCV Microlisa was an in vitro qualitative enzyme 
linked immunosorbent assay for the detection of antibodies against HCV (Anti-
HCVs) in human serum or plasma.  This HCV Microlisa Kit was supplied by J. 
Mira & Co. Pvt .Limited. The technique of ELISA was performed as per the   
manufacturer guidelines. 
PRINCIPLE OF THE ASSAY: 
The third generation HCV Microlisa was based on a highly sensitive 
technique, enzyme linked immunosorbent assay which detects antibodies 
against HCV in human serum and plasma. The HCV proteins are in serum at 
levels well below the limits of detection. Thus immune diagnosis of HCV 
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infection was based on detection of host generated antibodies (Anti-HCVs) to 
viral proteins. 
 SPECIMEN COLLECTION & HANDLING 
 Blood samples were collected into a test tube and centrifuged at 
3000rpm for 10 minutes and the supernatant serum was removed. 
 Serums were stored at -20ºC or lower. 
 TEST PROCEDURE 
1. About 100 μl of sample diluents was added to the first well as blank. 
2. About 100 μl Negative Control added to each well B-1. 
3. Positive Control 100 µl  was added to wells C-1, D-1 & E-1 
4. In the next step100 μl of sample diluents was added to each well, from 
F1followed by 10μl of sample was added. 
5. The plate was covered with seal and incubated at 37ºC + 2ºC for 
30minutes 
6. Working wash solution and working conjugate was prepared during 
incubation of samples. 
7. After incubation, the plate was taken from incubator and washed with 
wash buffer. 
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8. 100µl of Working Enzyme conjugate was added to each well including 
A1.  
9. The plate was covered and incubated at 37ºC + 2ºC for 30minutes. 
10. After incubation, the plate was washed six times with wash buffer. 
11. 100µl of Working substrate was added to each well including A1. 
12. Aluminium foil was used to cover the plates and incubated at 20-25°C 
for 30 minutes in dark. 
13. Stop solution was added (100 μl) to each well. 
14. The Absorbance values were read at 450nm in an Elisa Reader. 
CALCULATION OF RESULTS 
Test Validity: 
 Blank must be < 0.100 in case of differential filter being used. 
 PC or PCx must be >0.5. If it is not so, the run is invalid and must be 
repeated. 
 Mean absorbance, PCx = 5.610/3 = 1.870 
 NC must be < 0.150 
Cut-off value can be determined by using the following formula: 
 Cut-off Value = PCx X 0.23 
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INTERPRETATION OF RESULTS 
The absorbance of the unknown sample is compared with the calculated 
cut-off value. 
Test specimens with absorbance (O.D.) value less than cut-off value 
were regarded non-reactive and were considered as negative for Anti HCV. 
Test specimens with absorbance (O.D.) value greater than or equal to 
cut off value were considered reactive for Anti HCV MICROLISA. 
DETECTION OF HEPATITIS B SURFACE ANTIGEN (HBSAG) BY         
ENZYME LINKED IMMUNOSORBENT ASSAY: 
Detection of Hepatitis B surface Antigen (HBsAg) in human serum or 
plasma by enzyme linked   immunosorbent assay with Hepalisa kit.  This 
Hepalisa Kit was supplied by J. Mitra & Co. Pvt .Limited. The technique of 
Elisa was performed as per the manufacturer guidelines. 
PRINCIPLE OF THE ASSAY: 
HEPALISA is a solid phase enzyme linked immunosorbent assay 
(ELISA) based on the “Direct Sandwich” principle. The microwells were 
coated with Monoclonal antibodies with high reactivity for HBsAg. The 
samples   were added in the wells followed by addition of enzyme conjugate 
(polyclonal antibodies linked to Horseradish Peroxidase (HRPO). A sandwich 
complex was formed in the well wherein HBsAg (from serum sample) was 
“trapped” or “sandwiched” between the antibody and antibody HRPO 
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conjugate. Unbound   conjugate was washed off with wash buffer. The amount 
of bound peroxidase was proportional to the concentration of HBsAg present in 
the sample. Upon addition of the substrate buffer and chromogen, a blue colour 
develops. The intensity of developed blue colour was proportional to the 
concentration of HBsAg present in the sample.  
SPECIMEN COLLECTION & HANDLING 
o Blood samples were collected into a test tube and centrifuged at 
3000rpm for 10 minutes and the supernatant serum was removed. 
o Serums were stored at -20ºC or lower. 
TEST PROCEDURE 
1. The first well A-1 as blank. 
2. About 100 μl Negative Control added to each well B-1and C-
1respectively. 
3. Positive Control 100 µl  was added to wells, D-1 & E-1 
4. In the next step100 μl of sample was added to each well. 
5. Added 50μl of Enzyme conjugate to each well except A1 
6. The plate was covered with seal and incubated at 37ºC + 1ºC for 
60minutes 
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7. After incubation, the plate was taken from incubator and washed with 
wash buffer. 
8. 100µl of Working substrate was added to each well includingA1. 
9. Aluminium foil was used to cover the plates and incubated at 20-25°C 
for 30 minutes in dark. 
10. Stop solution was added (100μl) to each well. 
11. The Absorbance values were read at 450nm in an Elisa Reader. 
CALCULATION OF RESULTS 
Test Validity: 
 Blank must be < 0.100 in case of differential filter being used. 
 PC or PCx must be >0.5. If it is not so, the run is invalid and must be 
repeated. 
 Mean absorbance, PCx = 1.430+1.500=2.930÷2= 1.465 
 Mean absorbance, PCx= 1.465. 
 NC must be < 0.150 
 NC=0.012+0.010=0.022 
 Mean absorbance, NCx= 0.022/2= 0.011 
Cut-off value can be determined by using the following formula: 
 Cut-off Value = NCx + 0.1 
63 
 
INTERPRETATION OF RESULTS 
The absorbance of the unknown sample is compared with the calculated 
cut-off value. 
Test specimens with absorbance (O.D.) value less than cut-off value 
were regarded non-reactive and were considered as negative for HBsAg. 
Test specimens with absorbance (O.D.) value greater than or equal to 
cut off value were considered reactive for HBsAg. 
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RESULTS 
Total number of 150 patients with DCLD with signs and symptoms of 
bacterial  infections (who satisfied the inclusion criteria) were included in this 
study from September 2013 to August 2014 (one year) 
TABLE 1: ANALYSIS OF SEX DISTRIBUTION IN DCLD PATIENTS 
( n=150)  
 
 
 
 
 
Among 150 patients (n = 150),  97%  were males and 3% were females. 
Males were predominantly affected groups than female in DCLD. It might be 
due to  more distribution of male patients with DCLD than female. 
SEX No. of  patients 
Male 145 (97%) 
Female 5(3%) 
Total 150(100%) 
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CHART1: ANALYSIS OF SEX DISTRIBUTION IN DCLD PATIENTS 
 
TABLE 2: ANALYSIS OF AGE DISTRIBUTION OF ALL PATIENTS 
WITH DCLD( n=150) 
Majority of patients  belonged to 41-50years (33.33%) of age group 
followed by 31-40 years (29.33%), 51-60 years (26%) of age. Age groups of 
less than  30years and more than 60 years were less commonly involved in this 
study. 
S.no. Age Male Female Total 
1 ≤ 30years 
8(5.33%) 
1(0.67%) 
9 (6%) 
 
2 31-40 years 44(29.33%) - 44(29.33%) 
3 41-50 years 49(32.67%) 1(0.66%) 50(33.33%) 
4 51-60 years 37(24.67%) 2(1.33%) 39(26%) 
5 ≥60years 7(4.66%) 1(0.67%) 8(5.33%) 
 Total 145(97%) 5(3%) 150(100%) 
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CHART 2: ANALYSIS OF AGE DISTRIBUTION IN PATIENTS     
WITH  DCLD 
 
TABLE 3:SAMPLES DISTRIBUTION AND BACTERIAL INFECTIONS 
IN DCLD PATIENTS ( n = 150 ) 
S. no Type of sample 
Number of 
sample (%) 
(n=150) 
Culture 
positive (% ) 
(n=81) 
1 
Ascitic fluid –Spontaneous 
bacterial peritonitis 
59 (39.33%) 22 (27%) 
2 Urine- UTI 44 (29.33%) 21 (26%) 
3 Sputum- Pneumonia 27 (18.00%) 13 (16%) 
4 Wound swab- Skin infections 20 (13.33%) 10 (12%) 
5 
Blood- Spontaneous 
bacteraemia 
150 (100%) 15 (19%) 
Out of 150 patients, the common samples received and processed were 
ascitic fluid (39.33%), followed by urine (29.33%), sputum (18%) and wound 
swab (13.33%). Blood sample was collected from all the 150 (100%) patients. 
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              Among 150 patients of DCLD, 81(54%) patients were culture positive. 
Of which, spontaneous bacterial peritonitis 22(27%) were common, followed 
by urinary tract infection 21(26%), spontaneous bacteraemia 15(19%), 
pneumonia 13(16%) and skin and soft tissues infection 10(12%). 
CHART 3: DISTRIBUTION OF CULTURE POSITIVITY IN VARIOUS 
TYPES OF SAMPLES  IN DCLD PATIENTS 
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TABLE- 4: CAUSES OF DCLD 
The main causes of decompensated liver disease was Alcoholic liver 
disease(84%), followed by viral hepatitis (10%), both alcoholic liver diseases 
and viral hepatitis  together (5.34%) and Cryptogenic causes(0.66%). 
CHART-4: PERCENTAGE OF CAUSES OF DCLD 
 
S. no. Cause Percentage 
1 Alcoholic liver disease 126(84%) 
2 Viral hepatitis 15(10%) 
3 Both Alcoholic liver diseases and Viral hepatitis 8(5.34%) 
4 Cryptogenic 1(0.66%) 
 Total 150 (100%) 
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TABLE 5: ANALYSIS  OF CULTURE POSITIVITY IN VARIOUS AGE 
GROUP ( n = 150) 
The age groups 41 to 50 years were most commonly affected with 
bacterial  infections, followed by 51- 60 years and 31- 40 years.  
S.No. Age 
CULTURE 
POSITIVE 
CULTURE 
NEGATIVE 
TOTAL 
1 ≤ 30years 4[2.67%] 5 [3.33%] 9 [6%] 
2 31-40 years 20 [13.33%] 24 [16%] 44 [29.33%] 
3 41-50 years 32 [21.33%] 18 [12%] 50 [33.33%] 
4 51-60 years 20 [13.33%] 19 [12.66%] 39 [26%] 
5 ≥60years 5 [3.34%] 3 [2%] 8 [5.34%] 
 Total 81[54%] 69 [46%] 150 [100%] 
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CHART-5: ANALYSIS  OF CULTURE POSITIVITY IN VARIOUS AGE 
GROUP ( n = 15O) 
 
TABLE 6 : DETECTION OF  GNB AND GPC IN  VARIOUS TYPES OF 
BACTERIAL INFECTIONS IN DCLD 
Type of infections in DCLD (n=11) 
GRAM              
POSITIVE 
COCCI 
GRAM 
NEGATIVE 
BACILLI 
Spontaneous bacterial peritonitis ( n=22 ) 6 (27%) 16(73%) 
Urinary tract infections (n=21) 1(5%) 20(95%) 
Spontaneous bacteraemia (n=15) 7(47%) 8(53%) 
Pneumonia(n=13) 0 13(100%) 
Skin & soft tissues infections (n=10) 4(40%) 6(60%) 
Total  81 18 (22%) 63(78%) 
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In this study, out of 81 culture positive isolates, 63(78%) were Gram 
Negative  bacilli and 18 (22%) were Gram Positive cocci. (P value = 0.005 – 
Highly significant). 
CHART-6 : DETECTION OF  GNB AND GPC IN  VARIOUS TYPES 
OF BACTERIAL INFECTIONS IN DCLD 
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TABLE 7:ANALYSIS OF BACTERIAL  ISOLATES FROM ASCITIC 
FLUID IN PATIENTS OF SBP WITH DCLD( n =22) 
S.No. Organisms 
Number  
[n = 22 ] 
Percentage 
1 Escherichia coli 7 31.82% 
2 Klebsiella  pneumoniae 3 13.63% 
3 Klebsiella oxytoca 1 4.54% 
4 Proteus mirabilis 1 4.54% 
5 Enterobacter cloacae 1 4.54% 
6 Citrobacter koseri 1 4.54% 
7 Pseudomonas  aeruginosa 1 4.54% 
8 Acinetobacter  baumanii 1 4.54% 
9 Staphylococcus aureus 4 18.18% 
10 Enterococcus faecalis 2 9.09% 
 TOTAL 22 100% 
In patients with spontaneous bacterial peritonitis (SBP) the most 
frequently isolated organisms were E. coli (31.82%),Staphylococcus 
aureus(18.18%), Klebsiella  pneumoniae(13.63%) and Enterococcus 
faecalis(9.09%). 
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CHART-7:ANALYSIS OF BACTERIAL  ISOLATES FROM ASCITIC 
FLUID IN PATIENTS OF SBP WITH DCLD 
 
TABLE 8:ANALYSIS OF BACTERIAL  ISOLATES FROM URINE IN 
PATIENTS OF URINARY TRACT INFECTIONS WITH DCLD ( n =21) 
S.no. Organisms Number (n=21) Percentage 
1 Escherichia coli 8 38.09% 
2 Klebsiella pneumoniae 3 14.28% 
3 Klebsiella oxytoca 6 28.57% 
4 Enterobacter cloacae 1 4.76% 
5 Acinetobacter baumanii 2 9.52% 
6 Enterococcus faecalis 1 4.76% 
 Total 21 100% 
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In urine samples, 21were culture positive. Of which Escherichia coli 
was the most common isolate (38.09%) followed by Klebsiella oxytoca 
(28.57%), Klebsiella pneumoniae (14.28%), Acinetobacter baumanii (9.52%) 
and Enterococcus faecalis (4.76%) 
CHART-8:ANALYSIS OF BACTERIAL  ISOLATES FROM URINE IN 
PATIENTS OF URINARY TRACT INFECTIONS WITH DCLD 
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TABLE 9:ANALYSIS OF BACTERIAL  ISOLATES FROM BLOOD IN 
PATIENTS OF BACTERIMIA WITH DCLD( n =15) 
S.No. Organisms Number [ n =15] Percentage 
1 Escherichia coli 2 13.33% 
2 Klebsiella pneumoniae 4 26.33% 
3 Pseudomonas  aeruginosa 2 13.33% 
4 Staphylococcus aureus 3 20.00% 
5 Streptococcus viridians 2 13.33% 
6 Staphylococcus epidermidis 2 13.33% 
 Total 15 100% 
Among 150 blood samples, 15 samples were culture positive. Of which 
Klebsiella pneumoniae (26.33%) was the most common isolate followed by 
Staphylococcus aureus (20.00%), Escherichia coli, Pseudomonas aeruginosa, 
Staphylococcus epidermidis and Streptococcus viridians. Two isolates 
(Klebsiella pneumoniae and Pseudomonas   aeruginosa) were isolated from 
ascitic fluid. 
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CHART-9:ANALYSIS OF BACTERIAL  ISOLATES FROM BLOOD IN 
PATIENTS OF BACTERAEMIA WITH DCLD 
 
TABLE 10:ANALYSIS OF BACTERIAL  ISOLATES FROM SPUTUM 
IN PATIENTS OF PNEUMONIA WITH DCLD( n =13) 
S.No. Organisms Number [ n =13] Percentage 
1 Escherichia coli 1 7.69% 
2 Klebsiella pneumoniae 3 23.07% 
3 Klebsiella oxytoca 6 46.14% 
4 Pseudomonas  aeruginosa 3 23.07% 
 Total 13 100% 
Out of 27 sputum samples, 13 samples were culture positive. Klebsiella 
oxytoca (46.14%) was the most common isolate followed by Klebsiella 
pneumoniae  (23.07%) Pseudomonas aeruginosa (23.07%) and Escherichia 
coli (7.69%).  
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CHART-10:ANALYSIS OF BACTERIAL  ISOLATES FROM SPUTUM 
IN PATIENTS OF PNEUMONIA WITH DCLD 
 
TABLE 11:ANALYSIS OF BACTERIAL  ISOLATES FROM WOUND 
SWABS IN PATIENTS OF SKIN INFECTION WITH DCLD( n =10) 
S.No. Organisms Number [ n =10] Percentage 
1 Escherichia coli 1 10% 
2 Klebsiella pneumoniae 1 10% 
3 Proteus vulgaris 3 30% 
3 
Pseudomonas  
aeruginosa 
1 10% 
4 Staphylococcus aureus 
 
2 
20% 
6 
Staphylococcus 
epidermidis 
2 20% 
 Total 10 100% 
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Out of 18 wound swab, 10 were culture positive. Proteus vulgaris (30%) 
was the main isolates followed by Staphylococcus aureus (20%), Staphylococcus 
epidermidis (20%), Escherichia coli (10%) and Klebsiella pneumoniae (10%). 
CHART-11:ANALYSIS OF BACTERIAL  ISOLATES FROM WOUND 
SWAB IN PATIENTS OF SKIN INFECTION WITH DCLD 
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TABLE 12: ANTIMICROBIAL SUSCEPTIBILITY PATTERN FOR GRAM NEGATIVE ISOLATES IN SBP FROM 
PATIENTS   WITH DCLD. (n=16) 
Name of the 
Antibiotics 
E.coli 
(n=7) 
Klebsiella 
pneumoniae 
(n=3) 
Klebsiella 
oxytoca 
(n=1) 
Enterobacter 
cloacae 
(n=1) 
Citrobacter 
koseri  
(n=1) 
Proteus 
mirabilis 
(n=1) 
P.aeruginosa 
(n=1) 
Acinetobacter 
baumanii 
(n=1) 
no % no % no % no % no % no % no % no % 
Amikacin 6 86 2 67 1 100 1 100 1 100 1 100 1 100 1 100 
Gentamicin 5 71 1 33 1 100 0 0 0 100 1 100 1 100 1 100 
Ceftazidime 3 28 1 33 1 100 0 0 1 100 1 100 1 100 1 100 
Cefotaxime 3 28 1 33 1 100 0 0 1 100 1 100 - - 1 100 
Ciprofloxacin 7 100 3 100 1 100 1 100 1 100 1 100 0 0 1 100 
Ampicillin 7 100 3 100 1 100 0 0 1 100 1 100 0 0 1 100 
Cotrimoxazole 6 86 3 100 1 100 1 100 1 100 1 100 0 0 1 100 
Piperacillin / 
Tazobactum 
7 100 3 100 1 100 1 100 1 100 1 100 1 100 1 100 
Imipenem 7 100 3 100 1 100 1 100 1 100 1 100 1 100 1 100 
Tetracycline 7 100 2 67 1 100 1 100 1 100 1 100 1 100 1 100 
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All the GNB isolated from spontaneous bacterial peritonitis were100% 
sensitive to imipenam Mostly sensitive to Amino glycosides and 
fluoroquinolones. 
Out of 16 GNB, 56% only showed sensitivity to third generation 
cephalosporins. Pseudomonas aeruginosa isolate as showed 100% sensitivity  
to ceftazidime.  Acinetobacter baumanii showed 100% sensitivity to all other 
drugs used against for GNB. 
TABLE 13: ANTIMICROBIAL  SUSCEPTIBILITY PATTERN FOR 
GRAM POSITIVE COCCI IN  SBP PATIENTS   WITH  DCLD.(n=6) 
Name of the 
Antibiotics 
Staphylococcus aureus 
(n=4) 
Enterococcus faecalis 
(n=2) 
no % no % 
Amikacin 4 100 - - 
Gentamicin 3 75 - - 
Ciprofloxacin 3 75 - - 
Ampicillin 3 75 2 100 
Cotrimoxazole 3 75 - - 
Tetracycline 3 75 0 0 
Chloramphenical - - 2 100 
Amoxycillin - - - - 
Erythromycin 2 50 2 100 
Cefoxitin 2 50 - - 
HL Gentamicin  - - 2 100 
Penicillin 3 75 2 100 
Vancomycin (MIC) 2 50 1 50 
 50% of Staphylococcus aureus were Methicillin sensitive. 
 50% of Enterococcus faecalis were vancomycin sensitive Enterococci 
(VSE). Enterococcus faecalis were 100% sensitive to all other drugs 
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TABLE 14: ANTIMICROBIAL   SUSCEPTIBILITY PATTERN OF 
URINARY ISOLATES FROM DCLD PATIENTS (n=20) 
Name of the 
Antibiotics 
E.coli 
(n=8) 
Klebsiella 
pneumoni
ae 
(n=3) 
Klebsiell
a 
oxytoca 
(n=6) 
Enterobact
er 
cloacae 
(n=1) 
Acinetobact
er baumanii 
(n=2) 
n
o 
% no % no % no % no % 
Amikacin 7 88 3 100 4 67 1 100 1 50 
Gentamicin 4 50 3 100 3 50 1 100 1 50 
Ceftazidime 3 37 1 33 1 17 1 100 0 0 
Cefotaxime 3 37 1 33 1 17 1 100 0 0 
Ciprofloxacin 5 62 3 100 3 50 1 100 1 50 
Norfloxacin 4 50 1 33 2 33 1 100 0 0 
Nitrofurantoin 1 13 2 33 2 33 1 100 2 100 
Cotrimoxazole 6 75 3 100 4 67 1 100 2 100 
Piperacillin / 
Tazobactum 
5 62 3 100 5 83 1 100 2 100 
Imipenem 8 10
0 
3 100 6 100 1 100 2 100 
Chlorampheni
cal 
- - 3 100 5 83 1 100 - - 
Tetracycline 8 10
0 
3 100 6 100 1 100 2 100 
 Among urinary tract infections, all the GNB were 30% sensitive to third 
generation cephalosporins. 
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 Klebsiella pneumoniae was 100% sensitive to amino glycosides 
fluoroquinolones, carbapenems and piperacillin / Tazobactum. 
 Enterobacter cloacae was 100% sensitive to all other drugs.  
TABLE 15: ANTIMICROBIAL   SUSCEPTIBILITY   PATTERN FOR 
ENTEROCOCCUS FAECALIS IN URINARY ISOLATES FROM DCLD 
PATIENTS (n=1) 
Name of the Antibiotics 
Enterococcus faecalis (n=1) 
no % 
Tetracycline 1 100 
HL Gentamicin 0 0 
Penicillin 0 0 
Vancomycin 1 100 
Ampicillin 1 100 
Norfloxacin 1 100 
Nitrofurantoin 0 0 
 Enterococcus faecalis was 100% sensitive to vancomycin. 
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TABLE 16: ANTIMICROBIAL   SUSCEPTIBILITY PATTERN OF 
GRAM NEGATIVE ISOLATES FROM BLOOD OF DCLD PATIENTS 
(n=8) 
Name of the 
Antibiotics 
E.coli(n=2) 
Klebsiella 
pneumoniae(n=4) 
Pseudomonas  
aeruginosa (n=2) 
no % no % no % 
Amikacin 2 100 3 75 2 100 
Gentamicin 1 50 2 50 2 100 
Ceftazidime 1 50 3 75 1 50 
Cefotaxime 1 50 3 75 - - 
Ciprofloxacin 2 100 2 50 0 0 
Cotrimoxazole 2 100 2 50 - - 
Piperacillin / 
Tazobactum 
2 100 4 100 2 100 
Imipenem 2 100 4 100 2 100 
Tetracycline 2 100 4 100 2 100 
All the GNB isolated from blood showed 100% sensitive to amino 
glycosides, carbapenems and piperacillin / Tazobactum. 
 Out of 8 GNB in blood culture, 2 isolates (Klebsiella pneumoniae and 
Pseudomonas aeruginosa) were isolated from ascitic fluid with same 
sensitivity pattern. 
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TABLE 17: ANTIMICROBIAL SUSCEPTIBILITY PATTERN OF 
GRAM POSITIVE ISOLATES FROM BLOOD OF DCLD PATIENTS 
(n=7) 
Name of the 
Antibiotics 
Strep. viridans 
(n=2) 
S. aureus  (n=3) 
S.epidermidis 
(n=2) 
no % no % no % 
Amikacin - - 3 100 2 100 
Gentamicin - - 2 67 1 50 
Ciprofloxacin 2 100 3 100 2 100 
Ampicillin 2 100 2 67 1 50 
Cotrimoxazole 2 100 2 67 2 100 
Chloramphenical 1 50 - - - - 
Tetracycline 1 50 2 67 1 50 
Amoxycillin - - - - - - 
Erythromycin 2 100 1 33 2 100 
Cefoxitin   2 67 2 100 
Penicillin 2 100 1 33 2 100 
Vancomycin 
(MIC) 
1 50 2 100 2 100 
 In Blood culture, Streptococcus viridians showed 100% sensitive to 
ciprofloxacin, ampicillin, cotrimoxazole and erythromycin. 
 Staphylococcus aureus were 67% sensitive to methicillin. 
 Staphylococcus epidermidis were showed 100% sensitive to methicillin, 
vancomycin and amino glycosides. 
 All the GPC were 100% sensitive to fluoroquinolones. 
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TABLE 18: ANTIMICROBIAL   SUSCEPTIBILITY PATTERN OF 
ISOLATES FROM PNEUMONIA OF DCLD PATIENTS (n= 13) 
Name of the 
Antibiotics 
E.coli 
(n=1) 
Klebsiella 
pneumoniae 
(n=3) 
Klebsiella 
oxytoca 
(n=6) 
Pseudomonas  
aeruginosa 
(n=3) 
no % no % no % no % 
Amikacin 1 100 1 33 4 67 3 100 
Gentamicin 0 0 1 33 3 50 3 100 
Ceftazidime 0 0 1 33 1 16 2 67 
Cefotaxime 0 0 1 33 1 16 2 67 
Ciprofloxacin 0 0 2 67 3 50 2 67 
Ampicillin 1 100 2 67 2 67 - - 
Cotrimoxazole 1 100 2 67 3 50 3 100 
Piperacillin / 
Tazobactum 
1 100 3 100 5 83 2 67 
Imipenem 1 100 3 100 5 83 3 100 
Tetracycline 1 100 3 100 5 83 3 100 
 In the sputum samples, among 13 GNB, 31% sensitive to third 
generation cephalosporins. 
 All the GNB were 100% sensitive to carbapenem except one Klebsiella 
oxytoca which was resistant to carbapenem. 
 No GPC was isolated from sputum samples.      
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TABLE 19: ANTIMICROBIAL SUSCEPTIBILITY PATTERN OF 
GRAM NEGATIVE ISOLATES FROM WOUND SWAB OF DCLD 
PATIENTS (n=6) 
Name of the 
Antibiotics 
E.coli 
(n=1) 
Klebsiella 
pneumoniae 
(n=1) 
Proteus vulgaris 
(n=3) 
Pseudomonas  
aeruginosa 
(n=1) 
no % no % no % no % 
Amikacin 1 100 0 0 2 67 1 100 
Gentamicin 1 100 1 100 2 67 1 100 
Ceftazidime 0 0 0 0 0 0 1 100 
Cefotaxime 0 0 0 0 0 0 0 0 
Ciprofloxacin 0 0 0 0 2 67 1 100 
Ampicillin 1 100 0 0 3 100 1 100 
Cotrimoxazole 1 100 1 100 2 67 1 100 
Piperacillin / 
Tazobactum 
1 100 1 100 3 100 1 100 
Imipenem 1 100 1 100 3 100 1 100 
Tetracycline 1 100 1 100 3 100 1 100 
 Pseudomonas aeruginosa was sensitive to all drugs. 
 Among GNB, 17 % sensitive to third generation cephalosporin. 
 E.coli was 100% sensitive to amino glycosides, piperacillin / 
tazobactum, Imipenem and gentamicin. 
 All the GNB were 100% piperacillin / tazobactum, imipenem and 
tetracycline 
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TABLE 20: ANTIMICROBIAL SUSCEPTIBILITY PATTERN OF 
GRAM POSITIVE ISOLATES FROM WOUND SWAB OF DCLD 
PATIENTS (n=4) 
Name of the Antibiotics 
Staphylococcus 
aureus(n=2) 
Staphylococcus 
epidermidis (n=2) 
no % no % 
Amikacin 2 100 1 50 
Gentamicin 1 50 1 50 
Ciprofloxacin 2 100 1 50 
Ampicillin 1 50 1 50 
Cotrimoxazole 2 100 2 100 
Tetracycline 2 100 2 100 
Erythromycin 2 100 2 100 
Cefoxitin 1 50 2 100 
Penicillin 1 50 2 100 
Vancomycin (MIC) 2 100 2 100 
 In our study, 50% of Staphylococcus aureus were Methicillin sensitive. 
 All the GPC were 100% sensitive to vancomycin 
88 
 
TABLE 21: DETECTION OF ESBL PRODUCTION FROM GRAM 
NEGATIVE ISOLATES IN DCLD PATIENTS 
S.no. 
Type of infections  
(GNB n=63) 
Screening 
Test 
DDST PCDDT 
no. % no. % no. % 
1. 
SBP  
[Total no of GNB=16] 
7 43.75 5 31.25 4 25 
2. 
Urinary tract infections 
[Total no of GNB = 20] 
14 70 12 60 11 55 
3. 
 Spontaneous 
Bacteraemia [Total no 
of GNB = 8] 
2 25 2 25 2 25 
 
4 
Pneumonia 
[Total no of GNB = 13] 
8 61.53 6 46.15 5 38 
5 
Skin & soft tissues 
infections  
[Total no of GNB = 6] 
4 66.66 4 66.66 3 50 
 Total 35 56% 27 43% 25 40% 
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DDST – Double disk diffusion synergy test 
PCDDT – Phenotypic Confirmatory disk diffusion test 
Majority of ESBL isolates 55% (11/20)  were from urinary tract infections 
followed by skin & soft tissues infections 50% (3/6), pneumonia 38% (5/13), 
spontaneous bacterial peritonitis 25% (4/16) and spontaneous bacteraemia 25% 
(2/8). 
CHART-12: DETECTION OF ESBL PRODUCTION IN DIFFERENT 
INFECTIONS OF DCLD 
 
90 
 
TABLE 22 :  INTERPRETATION OF MIC OF MEROPENEM FOR 
CARBAPENEMASE PRODUCING ENTEROBACTERIACEAE BY 
MACROBROTH DILUTION METHOD 
 
Name of isolates MIC value Interpretation 
Klebsiella oxytoca (1)  ≥16µg/ml Resistant 
INTERPRETATION:  
≤ 1µg/ml –     Susceptible 
2µg/ml – Intermediate 
≥4µg/ml – Resistant.  
TABLE 23: DETECTION OF  METHICILLIN RESISTANT 
STAPHYLOCOCCUS AUREUS IN  VARIOUS TYPES OF BACTERIAL 
INFECTIONS IN DCLD   (n=13) 
 
Type of infections in DCLD 
(Total no of GPC -13) 
MRSA 
Resistance % 
Spontaneous bacterial peritonitis ( n= 4) 2 50 
urinary tract infections (n=0) - - 
Spontaneous bacteraemia (n=5) 1 20 
Pneumonia(n=0) - - 
Skin & soft tissues infections (n=4) 1 25 
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Total of 13 GPC, 9 (69%) were Methicillin sensitive and 4(31%) were 
Methicillin resistant, of which 2(50%) of MRSA were isolated from 
spontaneous bacterial peritonitis, 1(25%) MRSA from spontaneous 
bacteraemia and 1(25%) MRSA from Skin & soft tissues infections. 
CHART-13: DETECTION OF METHICILLIN RESISTANT 
STAPHYLOCOCCUS AUREUS IN VARIOUS TYPES OF BACTERIAL 
INFECTIONS IN DCLD 
  
TABLE 24 :  INTERPRETATION OF MIC OF VANCOMYCIN FOR 
METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS BY 
MACROBROTH DILUTION METHOD 
 
Number of MRSA 
ISOLATES 
MIC value Interpretation 
4 ≤2µg/l Sensitive 
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INTERPRETATION 
≤ 2µg/ml –     Susceptible 
4-8µg/ml – Intermediate 
≥16µg/ml -   Resistant. 
TABLE- 25:  INTERPRETATION OF MIC OF VANCOMYCIN FOR 
ENTEROCOCCUS FAECALIS FROM ASCITIC FLUID BY 
MACROBROTH DILUTION   METHOD 
 
Enterococcus faecalis MIC value Interpretation 
              1  64µg/ml Resistant 
INTERPRETATION 
≤ 4µg/ml –  Susceptible 
8-16µg/ml – Intermediate 
≥32µg/ml -   Resistant 
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TABLE-26: ANTIBIOTIC RESISTANT PATTERN IN DIFFERENT 
TYPES OF INFECTIONS IN DCLD PATIENTS 
 
Type of infections in 
DCLD (n=81) 
ESBL 
(n=25) 
MRSA 
(n=4) 
VRE 
(n=1) 
MBL 
(n=1) 
no % no % no % no % 
Spontaneous bacterial 
peritonitis  ( n= 22) 
  
4 18 2 9 1 4.5 - - 
urinary tract infections 
(n=21) 
 
11 52 - - - - - - 
Spontaneous 
bacteraemia (n=15) 
 
2 13 1 7 - - - - 
Pneumonia(n=13) 5 38 - - - - 1 8 
Skin & soft tissues 
infections (n=10) 
3 30 1 10 - - - - 
In 81 culture-positive infections, 31 drug resistant bacterial infections 
were identified: 25 ESBL (81%), four Methicillin resistant Staphylococcus 
aureus(10%) one VRE (2.3%), and one MBL (2.3%). Of the culture-positive 
infections, these drug resistant bacterial infections occurred in 11 of 21 (52%) 
of the UTI cases, 7 of 22 (32%) of the SBP, 3 of 15 (20%) of the spontaneous 
bacteraemia cases, 6 of 13 (46%) of the pneumonia cases and 4 of 10 (40%) of 
the skin and soft tissue infection cases. 
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CHART-14: ANTIBIOTIC RESISTANT PATTERN IN DIFFERENT 
TYPES OF INFECTIONS IN DCLD PATIENTS 
 
TABLE- 27: SEROLOGICAL CORRELATION OF CAUSES OF DCLD 
(n=150) 
SEROLOGICAL  
TESTS DONE 
TEST 
POSITIVES 
Percentage 
HBsAg ELISA 12 8 
Anti HCV ELISA 11 7.3 
Total  23/150 15.3% 
Of the serological tests, Hepatitis B surface antigen was detected in 8% 
of the patients included in the study. Anti hepatitis C virus was found to be 
positive in 7.3% of the patients included in the study.  
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TABLE-28: DETECTION OF COMPLEMENT COMPONENT C3 
CONCENTRATION  BY ELISA 
NO. OF SAMPLE 
Total sample 
(n=88) 
CULTURE RESULT 
POSITIVE NEGATIVE 
Value less than 0.4mg/ml 59(67%) 35 (59%) 24 (41%) 
Value more than0.4mg/ml 29(33%) 4 (14%) 25 (86%) 
CHART-15: DETECTION OF COMPLEMENT COMPONENT C3 
CONCENTRATION BY ELISA 
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 Total samples of 150, Complement C3 ELISA were done for randomly 
selected 88 samples with one kit due to economic constrains.  
 Out of 88 patients, 67% patients were having low complement C3 level. 
Of which 59% patients were culture positive and 41% were culture 
negative. 
 33% had normal complement C3 level, of which.86% were culture 
negative and 14% were culture positive. 
  (P value = 0.001 – Highly significant) 
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DISCUSSION 
This study was conducted in the Institute of Microbiology, Madras 
Medical College, in association with other departments (Internal Medicine, 
Gastroenterology, and Hepatology etc), at Rajiv Gandhi Government General 
Hospital, Chennai. Total number of 150 DCLD patients with signs and 
symptoms of bacterial infections (who satisfied the inclusion criteria) were 
included in this study. 
Among 150 DCLD patients, males 145 (97%) were predominant group 
when compared to females 5(3%).(TABLE-1). This predilection of higher 
frequency rates among male is attributed towards the presence of underlying 
risk factors like alcoholism 
[134]
. Mathurin S et al 
[13]
 2009 has reported that 
DCLD incidence rates are more frequently observed in males (94.8%) when 
compared with females at all age groups. 
The common age groups, belonged to 41-50years (33.33%), and 
followed by 31-40 years (29.33%), 51-60years (26%) of age. Less than 30years 
were less commonly involved in this study (TABLE-2,5). These 41-50years 
age group patients with DCLD had low complement level and also had low 
phagocytic activity in serum and ascitic fluid, which predisposed to bacterial 
infections.  Basra S et al 2011
[131]
 has reported that the majority of cirrhosis 
occurred before the age of 60years and Hoefs 2002 et al 
[132] 
has reported that 
the similar age group 41-60 years, more commonly involved in bacterial 
infections in DCLD patients. 
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 In our study, the main causes of decompensated liver disease was 
alcoholic liver diseases (84%), followed by viral hepatitis (10%), both 
alcoholic liver diseases with viral hepatitis (5.34%) and Cryptogenic –cause 
unknown (0.66%) (TABLE - 4). Acetaldehyde is a metabolic product of 
alcohol which is excreted by liver and it may interact with proteins and 
membrane lipids, causing alterations in their structure and function of liver, 
which may lead to cell injury and cell death and causes cirrhosis
. 
Since 
Hepatitis C virus (HCV) itself is not cytopathic, liver damage in chronic 
hepatitis C is commonly leads to immune- mediated mechanism if the same 
patient consumed heavy alcohol which will accelerates this progression of liver 
damage into cirrhosis. Alcohol and hepatitis C virus (HCV) act synergistically 
to increases the incidence of cirrhosis. Mathurin S et al 
[13]
 2009 has reported 
that the alcoholic etiology for DCLD was 95.4%. Study conducted by Singal 
AK et al 2007
[26]
 and Ashwani K singh et al 2011
[27]
 reported that the 
concomitant alcohol abuse and hepatitis C virus occur in about 14% of 
individuals with chronic liver disease. 
 
Among 150 patients of DCLD, 81(54%) were culture positive (TABLE-
3). In 81 culture positive isolates, 63(78%) were Gram Negative bacilli and 18 
(22%) were Gram Positive cocci, which was correlated significantly [P value = 
0.005] (TABLE-6). In decompensated liver disease (DCLD) patients, the most 
common isolates were Gram negative bacilli which may be due to translocation 
of normal flora (most of the normal flora in the GIT are GNB) from the gastro 
intestinal tract. Among bacterial infections, Escherichia coli were the most 
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common pathogen (24%). Study conducted by.Borzio M et al 2001
[18]
 showed 
that the Escherichia coli was the most frequent pathogen (25%).  
In this study, the majority of samples received and processed were 
ascitic fluid (39.33%), followed by urine (29.33%), sputum (18%) and wound 
swab (13.33%). Blood sample was collected from all the 150 (100%) patients. 
Among culture positive infections , spontaneous bacterial peritonitis  (27%) 
was the most common infection due to translocation of enteric organisms from 
the intestine to the peritoneum and diagnostic and therapeutic paracentesis were 
predisposed to bacterial infections, followed by urinary tract infection (26%), 
spontaneous  bacteraemia (19%),  pneumonia (16%) and skin and soft tissues 
infection (12%) (TABLE - 3).  Similar results were obtained in studies 
conducted by Puneetha   Tandon et al 
[36] 
2012, Mathurin S et al 
[13]
 2009 and 
Borizia M et al 
[32]
.    
In patients with spontaneous bacterial peritonitis (SBP) (27%) the most 
frequently isolated organisms was E.coli (31.82%) as it is the commonest 
enteric pathogen, followed by Staphylococcus aureus (18.18%), Klebsiella 
pneumoniae (13.63%) and Enterococcus faecalis (9.09%) (TABLE- 7). Similar 
results were obtained in studies conducted by Hoefs 2002 et al 
132,
 Weinstein 
2000 et al 
135 
and
.
 Rimland et al 2007 et al
136]
.Two isolates (Pseudomonas 
aeruginosa and Klebsiella pneumoniae ) were  isolated from both ascitic fluid 
and blood with same sensitivity pattern. 
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In this study, among 44 urine samples, 21 (26%) were culture positive. 
Of which Escherichia coli (38.09%) were the most common isolates followed 
by Klebsiella oxytoca (28.57%), Klebsiella pneumoniae (14.28%), 
Acinetobacter baumanii (9.52%) and Enterococcus faecalis (4.76%)  (TABLE 
- 8). The incidence of urinary tract infection (UTI) is higher in decompensated 
cirrhotic patients with indwelling urinary catheters. Maria Pleguezuelo et al 
[11]
 
2013 has reported that the most frequent bacteria causing urinary tract 
infections (UTI) in DCLD patients were E. coli and Klebsiella spp. 
Among 150 blood samples, 15 (19%) samples were culture positive. Of 
which Klebsiella pneumoniae (26.33%) was the most common isolate followed 
by Staphylococcus aureus (20.00%), Escherichia coli, Pseudomonas 
aeruginosa, Staphylococcus epidermidis and Streptococcus viridians (TABLE-
9).  The Porto systemic shunt circulation in DCLD patients will favour the 
organisms to escape from phagocytosis by hepatic reticuloendothelial system, 
there by establishing systemic bacteraemia. Out of 15 blood culture positive 
samples, 2 (Klebsiella pneumoniae and Pseudomonas aeruginosa) isolates 
were isolated from ascitic fluid also. Rooby Erachamveettil Hamza et al 2014 
[137]
 has reported that the spontaneous bacteraemia is mainly caused by Gram 
negative bacilli followed by Gram positive cocci. 
In the sputum samples, 13(16%) samples were culture positive. 
Klebsiella oxytoca (46.14%) was the most common isolates followed by 
Klebsiella pneumoniae (23.07%)  Pseudomonas aeruginosa (23.07%) and 
Escherichia coli (7.69%) (TABLE-10). Some procedures like tracheal 
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intubation, oesophageal tamponade, and clinical conditions such as hepatic 
encephalopathy, and alcoholism  were clearly predisposing factors for 
pneumonia in cirrhotic patients.Study conducted by Stefano Fagiuolia et al 
[143]
 
2013 reported that the prevalence of pneumonia in DCLD patients was 15% . 
Out of 18 wound swabs, 10(12%) were culture positive. Proteus 
vulgaris (30%) was the main isolate followed by  Staphylococcus aureus(20%), 
Staphylococcus epidermidis (20%), Escherichia coli and  Klebsiella 
pneumoniae (TABLE-11). Lymphangitis of the lower extremities and 
abdominal wall are frequent in cirrhotic patients with edema or ascites which 
will leads to skin and soft tissue infections in DCLD patients. Study conducted 
by Rooby Erachamveettil Hamza et al 2014 
[137]
 and Mohan et al 2011
[144]
 
reported that the prevalence of skin infections in cirrhosis was 10.5-12.5% and 
the major etiological organisms were Staphylococcus aureus and gram negative 
bacilli. This is in my study which showed Proteus vulgaris (30%) as the main 
isolate. 
In the present study, all the GNB isolated from spontaneous bacterial 
peritonitis were100% sensitive to imipenem and  most of the isolates were 75% 
sensitive to amino glycosides and fluoroquinolones. Out of 16 GNB, 56% only 
showed sensitive to third generation cephalosporins. Pseudomonas aeruginosa 
isolate showed 100% sensitivity to ceftazidime. Acinetobacter baumanii 
showed 100% sensitive to all the drugs used against for GNB (TABLE-12). In 
GPC, Staphylococcus aureus showed 50% sensitive to methicillin and 100% 
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sensitive to vancomycin. Enterococcus faecalis were 50% sensitive to 
vancomycin and 100% sensitive to all other drugs (TABLE-13).  
Among urinary tract infections, all the GNB were 30% sensitive to third 
generation cephalosporins. Klebsiella pneumoniae was 100% sensitive to 
amino glycosides, fluoroquinolones carbapenem and piperacillin / Tazobactum. 
Enterobacter cloacae were 100% sensitive to all other drugs (TABLE-14). 
Enterococcus faecalis was 100% sensitive to vancomycin (TABLE-15). 
In our study, all the GNB isolated from blood showed 100% sensitive to 
amino glycosides, carbapenem and piperacillin / Tazobactum. Out of 8 GNB in 
blood culture, 2 isolates (Klebsiella pneumoniae and Pseudomonas 
aeruginosa) were isolated from ascitic fluid with same sensitivity pattern 
(TABLE-16). Streptococcus viridians showed ciprofloxacin, ampicillin, 
cotrimoxazole and erythromycin. Out of 5 Staphylococcus spp, 3isolates were 
Staphylococcus aureus and 2 isolates were Staphylococcus epidermidis.  All 
the Staphylococcus aureus and Staphylococcus epidermidis showed 100% 
sensitive to vancomycin by minimum inhibitory concentration method. 
Staphylococcus aureus were showed 67% sensitive to methicillin. All the Gram 
positive cocci (GPC) were 100% sensitive to fluoroquinolones (TABLE-17). 
In the sputum samples, among GNB, 31% of isolates were sensitive to 
third generation cephalosporins. All the GNB were 100% sensitive to 
carbapenem except one Klebsiella oxytoca which was resistant to carbapenem 
(TABLE-18).  No Gram positive cocci was isolated from sputum samples 
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In skin infections, among Gram Negative bacilli (GNB), 17 % were 
sensitive to third generation cephalosporin. Pseudomonas aeruginosa was 
sensitive to all the drugs. E.coli was 100% sensitive to amino glycosides, 
piperacillin / tazobactum, Imipenem and gentamicin. All the Gram Negative 
bacilli (GNB) were 100% piperacillin / tazobactum, imipenem and tetracycline 
(TABLE-19). 50% of Staphylococcus aureus were sensitive to methicillin and 
50% of Staphylococcus aureus were resistant to methicillin. All the GPC were 
100% sensitive to vancomycin by minimum inhibitory concentration method 
(TABLE-20). 
Among 63 (78%) were Gram Negative bacilli, 25of 63 (43%) were 
ESBL producer. Of which, majority of ESBL isolates 11 (55%)  were from 
urinary tract infections followed by 3 (50%) from skin & soft tissues infections, 
5 (38%) from pneumonia, 4 ( 25%) from spontaneous bacterial peritonitis and 
2 (25%) from spontaneous bacteraemia (TABLE- 21).  One MBL producing 
Klebsiella oxytoca was isolated from the sputum sample (TABLE-22). Javier 
Fernandez et al 2013 has reported that the increased prevalence of infections 
caused by multiresistant bacteria in cirrhosis  of which  extended-spectrum β-
lactamase–producing Enterobacteriaceae are more common. 
Total of 13 Gram positive cocci (GPC), 9 (69%) were Methicillin 
sensitive and 4(31%) were Methicillin resistant, of which 2 (50%)  MRSA 
isolates were from spontaneous bacterial peritonitis, 1(25%) MRSA isolated 
from spontaneous bacteraemia and 1(25%) MRSA isolate from Skin & soft 
tissues infection (TABLE-23, 24). 
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In our study, three (3) Enterococcus faecalis were isolated. Of which 
two Enterococcus faecalis were isolated from ascitic fluid and one 
Enterococcus faecalis was isolated from urine sample. Among the ascitic fluid 
isolates, One Enterococcus faecalis was resistant vancomycin (VRE) by 
minimum inhibitory concentration method (TABLE 25). 
In 81 culture-positive isolates, 31 were drug resistant bacterial infections 
were identified: 81% (25of 31) were ESBL , 13% (4/31) were Methicillin 
resistant Staphylococcus aureus , 3% (1/31) were vancomycin resistant 
Enterococci (VRE) , and 3% (1/31) were MBL (3%) (TABLE-26). Of the 
culture-positive isolates, these drug resistant bacterial infections occurred in 11 
of 21 (52%) of the urinary tract infections (UTIs), 7 of 22 (32%) of the 
spontaneous bacterial peritonitis (SBP), 3 of 15 (20%) of the spontaneous 
bacteraemia cases, 6 of 13 (46%) of the pneumonia and 4 of 10 (40%) of the 
skin and soft tissue infection cases. Early and unnecessary use of higher 
antibiotics like third generation cephalosporins, leads to increase in the 
occurrence of new resistant strains. The same results obtained by Puneeta 
Tandon et al 2012 
[145]
 and Fernandez J et al 2012 
[146] 
 
In our study, the prevalence rates of Hepatitis B surface antigen and 
Anti hepatitis C virus (HCV) by serological methods (ELISA) were found to be 
8%  and  7.3% respectively (TABLE 27).  India is at the intermediate endemic 
level of hepatitis B (2-7%), with hepatitis B surface antigen (HBsAg) 
prevalence between 2% to 10% among the populations studied.  
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Out of 150 total samples, Complement component C3 ELISA was done 
for randomly selected 88 samples with one kit due to economic constrains. Out 
of 88 patients, 59(67%) patients had low complement component C3 
concentration level. Of which 35(59%) patients were culture positive and 
24(41%) were culture negative. Among 29(33%) DCLD patients with normal 
complement component C3 concentration level, 25(86%) were culture negative 
and 4(14%) were culture positive (TABLE 28). Complement component C3 
concentration level in serum were decreased in decompensated cirrhotic 
patients with infections compared with decompensated cirrhotic patients 
without  infections . Concentrations of complement component C3 level 
significantly correlated (p=0.001) with decompensated liver disease (DCLD) 
patients with infections. Many studies conducted by Mustafa G et al 2007 
[80]
, 
Alper, C.A et al 
[81]
 and Colten H.R et al 1972
[82]
 reported that the complement 
is mainly synthesized by hepatocytes of liver. Due to cirrhosis, all the 
hepatocytes are destroyed and unable to synthesize complement component C3. 
This reduced level of complement C3 is the one of the risk factors for bacterial 
infections in DCLD patients 
[139, 141]
.                                          
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SUMMARY 
 Around 150 DCLD patients, who fulfilled the inclusion criteria, were 
included in this study. 
 Males were most commonly affected with decompensated liver disease 
(DCLD) than female 
 The vast majority of age group included in this study was 41-60 years. 
 The commonest age group which showed most of the bacterial 
infections was between 41-50 age groups. 
 .The main causes of decompensated liver disease (DCLD) was alcoholic 
liver diseases (84%), followed by viral hepatitis (10%), both alcoholic 
liver diseases and viral hepatitis (5.34%) and Cryptogenic 
causes(0.66%) 
 In our study, the main sample received and processed was ascitic fluid 
(39.33%), followed by urine (29.33%), sputum (18%) and wound swab 
(13.33%). Blood sample was collected from all the 150 (100%) patients 
 The prevalence of culture positivity according to the present study was 
54% (81 / 150). 
 In 81 culture positive isolates, 63(78%) were Gram Negative bacilli and 
18 (22%) were Gram Positive cocci, which was correlated significantly 
[P value = 0.005] 
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 The prevalence of spontaneous bacterial peritonitis  was  27%, next 
prevalent bacterial infections in decompensated liver disease (DCLD) 
patients were urinary tract infection (26%), spontaneous bacteraemia 
(19%) pneumonia (16%) and skin and soft tissues infection (12%). 
 Escherichia coli (31.82%), was the most common isolates among the 
patients with spontaneous bacterial peritonitis (SBP) followed by 
Staphylococcus aureus (18.18%), Klebsiella pneumoniae (13.63%) and 
Enterococcus faecalis (9.09%) 
 Similarly, in urinary tract infections, Escherichia coli (38.09%) was the 
common isolate followed by Klebsiella oxytoca (28.57%), Klebsiella 
pneumoniae (14.28%), Acinetobacter baumanii (9.52%) and 
Enterococcus faecalis (9.52%). 
 Klebsiella pneumoniae (26.33%) was the most common isolate among 
decompensated liver disease (DCLD) patients with spontaneous 
bacteraemia followed by Staphylococcus aureus (20.00%), Escherichia 
coli, Pseudomonas aeruginosa, Staphylococcus epidermidis and 
Streptococcus viridians. 
 In pneumonia, Klebsiella oxytoca (46.14%) was the most common 
isolates followed by Klebsiella pneumoniae (23.07%) Pseudomonas 
aeruginosa (23.07%) and Escherichia coli (7.69%). No Gram positive 
cocci  (GPC) was isolated from sputum samples. 
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 Most of the organisms were sensitive to amino glycosides and 50% 
sensitive to fluoroquinolones. 
 All the GNB were 100% sensitive to carbapenem except for one isolate 
of Klebsiella oxytoca from sputum sample.   
 Among 63 (78%) Gram Negative bacilli, 25 (43%) were ESBL 
producer. Of which, majority of ESBL isolates 55% (11/20)  were from 
urinary tract infections followed by 50% (3/6) from skin & soft tissues 
infections, 38% (5/13) from pneumonia, 25% (4/16) from spontaneous 
bacterial peritonitis and 25% (2/8) from spontaneous bacteraemia. One 
MBL producing Klebsiella oxytoca was isolated from the sputum 
sample . 
 Total of 13 Gram positive cocci (Staphylococcus spp), 9 ( 69%) were 
Methicillin sensitive and 4(31%)  were Methicillin resistant, of which 
50% of MRSA isolated from spontaneous bacterial peritonitis , 25%  
from spontaneous bacteraemia and 25% from Skin infections. 
 Out of 13 Staphylococcus spp, only four [31%] isolates were methicillin 
resistant Staphylococcus aureus (MRSA) and they were found to be 
sensitive to vancomycin by minimum inhibitory concentration (MIC) by 
Macro broth dilution method. 
 In our study, three (3) Enterococcus faecalis were isolated. Of which 
two Enterococcus faecalis were isolated from ascitic fluid and one 
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Enterococcus faecalis was isolated from urine sample. One vancomycin 
resistant Enterococci (VRE) isolated from ascitic fluid 
 In 81 culture-positive isolates, 31 were drug resistant bacterial isolates 
were identified: 81% (25of 31) were ESBL , 13% (4/31) were 
Methicillin resistant Staphylococcus aureus , 3% (1/31) were 
vancomycin resistant Enterococci (VRE) , and 3% (1/31) were MBL 
(3%) . Of the culture-positive isolates, these drug resistant bacterial 
infections occurred in 11 of 21 (52%) of the urinary tract infections 
(UTIs), 7 of 22 (32%) of the spontaneous bacterial peritonitis (SBP), 3 
of 15 (20%) of the spontaneous bacteraemia cases, 6 of 13 (46%) of the 
pneumonia and 4 of 10 (40%) of the skin and soft tissue infection cases. 
 In our study, the prevalence of Hepatitis B surface antigen and Anti 
hepatitis C virus by serological methods (ELISA) were found to be 8%  
and  7.3% respectively. 
 Out of 88 patients, 59(67%) patients had low complement component 
C3 level. Of which 35(59%) patients were culture positive and 24(41%) 
were culture negative. 29(33%) had normal complement component C3 
level, of which 25(86%) were culture negative and 4(14%) were culture 
positive. 
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CONCLUSION 
Bacterial infections are more frequently seen in decompensated liver 
disease (DCLD) patients than those with compensated liver disease patients.  It 
is the most important cause of morbidity and mortality in decompensated liver 
disease (DCLD) patients     
Bacterial infections in decompensated liver disease are due to invasive 
practical procedures, malnutrition, derangement of gut flora – intestinal stasis, 
bacterial over growth, increased intestinal permeability, impaired host defence 
mechanisms against infection. In the host defence mechanisms, impaired 
function of the reticuloendothelial system, deficiency of complement 
component level mainly C3 and impaired opsonisation activity have been 
implicated in the pathogenesis of the increased susceptibility to infections in 
patients with decompensated liver disease (DCLD).  
In DCLD patients, the spontaneous bacterial peritonitis is the most 
common infection followed by urinary tract infections (UTI), spontaneous 
bacteraemia, pneumonia and skin infections.  
The vast majority of infections were caused by Gram negative bacilli 
than Gram positive cocci. In Gram negative bacilli, the common isolate was 
Escherichia coli. In Gram positive cocci, Staphylococcus aureus was the 
common isolate.  In culture positive infections, 50% drug resistant bacterial 
infections were identified, mainly ESBL followed by MRSA, VRE and MBL. 
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A definitive etiologic diagnosis with its antimicrobial susceptibility 
pattern is used to arrive at an appropriate antibiotic policy and to know the 
changing trends in the nature of the microbial agents. This will help in 
minimizing the emergence and spread of drug resistant pathogens to the 
community. 
Antibiotic prophylaxis must be restricted to selected patients with high 
risk for the development of bacterial infections. Encouraging the use of first 
line antibiotics and to avoid unnecessary use of higher antibiotics like third 
generation cephalosporins will help to reduce the occurrence of new resistant 
strains.  
Antibiotic de-escalation is a mechanism whereby the provision of 
effective initial antibiotic treatment is achieved while avoiding unnecessary 
antibiotic use that would promote the development of resistance strains. It is a 
key element within antimicrobial stewardship programs and treatment for 
serious bacterial infections. The embodiment of de-escalation is that based on 
microbiology results around the day 3 therapy point; the empiric antibiotic(s) 
that were started are stopped or reduced in number and/or narrowed in 
spectrum.  
So, early identification of the source of bacterial infections in 
decompensated liver diseases patients and appropriate antibiotic treatment can 
significantly reduce hospital stay and morbidity and improve survival rate. 
Figure -1: DIRECT GRAM STAINING FROM ASCITIC FLUID SHOWED 
PUS CELLS AND GRAM NEGATIVE BACILLI 
 
FIGURE 2:GROWTH OF KLEBSIELLA PNEUMONIAE ON MAC CONKEY 
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FIGURE 3:BIOCHEMICAL REACTIONS OF KLEBSIELLA 
PNEUMONIAE 
 
 
                      FIGURE 4:  ANTIBIOGRAM FOR ESCHERICHIA COLI 
 
 
FIGURE 5:NOVOBIOCIN SENSITIVE AND POLYMYXIN RESISTANT 
STAPHYLOCOCCUS EPIDERMIDIS 
 
FIGURE 6:METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS 
 
 
 
FIGURE 7:DOUBLE DISK DIFFUSION SYNERGY TEST FOR DETECTION 
OF ESBL 
                                
 
 
FIGURE 8: PHENOTYPIC CONFIRMATORY DOUBLE DISK TEST  
FOR DETECTION OF ESB 
 
                         
 
FIGURE 9:MINIMUM INHIBITORY CONCENTRATION (MIC) FOR 
DETECTING MEROPENEMRESISTANCE IN KLEBSIELLA OXYTOCA- 16µg/ml. 
 
FIGURE 10:MINIMUM INHIBITORY CONCENTRATION (MIC) FOR 
DETECTING VANCOMYCIN RESISTANCE IN ENTEROCOCCUS FAECALIS- 
64µg/ml. 
 
 
  
FIGURE 11:DETECTION OF HBsAg BY ENZYME LINKED 
IMMUNOSORBENT ASSAY 
 
FIGURE 12:EDETECTION OF ANTI HCV BY ENZYME LINKED 
IMMUNOSORBENT ASSAY 
 
 
FIGURE 13:HUMAN COMPLEMENT C3 ELISA KIT 
 
 
 
APPENDIX - I 
ABBREVIATIONS 
ATCC - American Type Culture Collections 
CFU - Colony forming unit 
CLSI - Clinical & Laboratory Standards Institute 
DCLD - Decompensated liver disease 
DDST - Double Disk Diffusion Synergy Test 
E.coli - Escherichia coli 
ESBL - Extended Spectrum Beta Lactamases 
GNB - Gram – Negative Bacilli 
GPC - Gram – Positive Cocci 
MBL - Metallo ß-Lactamases 
MIC - Minimum Inhibitory Concentration 
MRSA - Methicillin Resistant Staphylococcus aureus 
MSSA - Methicillin Sensitive Staphylococcus aureus 
PCDDT - Phenotypic Confirmatory Disk Diffusion Test 
RES - Reticuloendothelial system 
SBP - Spontaneus bacterial peritonitis 
UTI - Urinary tract infection 
APPENDIX II 
A. STAINS AND REAGENTS 
1. Gram staining 
 
Methyl violet (2%) l0g Methyl violet in 100ml absolute 
alcohol in 1 litre of distilled water 
(primary stain) 
Grams Iodine l0g Iodine in 20g KI (fixative) 
Acetone Decolourising agent 
Carbol fuchsin 1% Secondary stain. 
B. MEDIA USED  
1. Mac Conkey agar 
Peptone 
Sodium taurocholate 
Distilled Water 
Agar 
2% neutral red in 50% ethanol 
10% lactose solution 
 
20g 
5 g 
1 ltr 
20 g 
3.5ml 
l00ml 
Dissolve peptone and taurocholate in water by heating. Add agar and 
dissolve it in steamer. Adjust pH to 7.5. Add lactose and neutral red shake well 
and mix.Heat in free steam (100°C) for 1 hour, then autoclave at 115°C for 15 
minutes. 
2. Nutrient agar 
Peptic digest of animal tissue 5g 
Sodium chloride 5g 
Beef extract 1.5g 
Yeast extract 1.5g 
Agar 15gm 
Final pH 7.4±0.2  
Suspend 28 grams in 1000 ml distilled water. Heat to boiling to dissolve 
the medium completely and sterilized by autoclaving at 15 lbs pressure 
(120°C) for 15 minutes.  
3. Blood agar (5% sheep blood agar) 
Peptone l0g 
NaCl 5g 
Distilled water 1 Ltr 
Agar l0g 
Dissolve ingredients in distilled water by boiling, and add 5% sheep 
blood(sterile) at 55°C adjust pH to 7.4. 
4. Chocolate agar 
Sterile defibrinated blood 10 ml 
Nutrient Agar (melted) 100 ml 
When the temperature was about 75°C, sterile blood was added with 
constant agitation. After addition of blood, kept in water bath and heating 
was continued till the blood changed to chocolate colour. Cooled to about 50° 
C and poured about 15ml into petri dishes with sterile precaution. 
5. Mueller- Hinton Agar 
Beef infusion 300ml 
Caesein hydrolysate 17.5g 
Starch 1.5g 
Agar l0g 
Distilled water lltr  
pH = 7.4 
Sterilise by autoclaving at 121°C for 20 mins 
6.  Robertson's Cooked Meat Broth 
Fresh bullock heart 5 00g 
Water 500ml 
Sodium hydroxide, lmol/1 1.5ml 
Liquid filtered from cooked meat 500ml 
Peptone 2.5g 
NaCl 1.25g 
7. Thioglycollate broth 
Pancreatic digest of casein 15gms 
Yeast extract 5gms 
 Dextrose (Glucose)  5.5gms 
Sodium chloride 2.5gms 
L-Cystine 0.5gms 
 Autoclaved at 15 lbs pressure (121°C) for 20 minutes.  
Note: If more than the upper one-third of the medium has acquired a 
pink colour, the medium may be restored once by heating  in a water bath or  
until the pink colour disappears. 
C. MEDIA REQUIRED FOR BIOCHEMICAL IDENTIFICATION 
1. Oxidase Reagent 
Tetra methyl p-phenylene diamine dihyrochloride- 1% aqueous solution. 
2. Catalase 
3% hydrogen peroxide 
3. Indole test 
Kovac's reagent 
Amyl or isoamyl alcohol 150ml Para dimethyl amino benzaldehyde lOg 
Concentrated hydrochloric acid 50ml 
Dissolve the aldehyde in the alcohol and slowly add the acid. Prepare in small 
quantities and store in the refrigerator. Shake gently before use. 
4. Christensen's Urease test medium 
Peptone lg 
Sodium chloride 5g 
Dipotassium hydrogen phosphate 2g 
Phenol red  6ml 
Agar  20g 
Distilled water  1 ltr 
10% sterile solution of glucose  10ml 
Sterile 20% urea solution  100ml 
Sterilize the glucose and urea solutions by filtration. Prepare the basal medium 
without glucose and urea, adjust to pH 6.8-6.9 and sterilize by autoclaving in a flask at 
121°C for 30min. Cool to about 50°C, add the glucose & urea, and tube the medium as 
slopes. 
5. Simmon's Citrate Medium 
Koser's medium 1 ltr 
Agar 20 g 
Bromothymol blue 0.2% 40ml  
Dispense, autoclave at 121°C for 15 min and allow to set as slopes 
6. Triple Sugar Iron medium 
Beef extract  3g 
Yeast extract  3g 
Peptone  20g 
Glucose  lg 
Lactose  10 g 
Sucrose  l0g 
Ferric citrate  0.3g 
Sodium chloride  5g 
S odum thiosulphate  0.3g 
Agar  12g 
Phenol red 0.2% solution  12ml 
Distilled water  1 ltr 
 
 Heat to dissolve the solids, add the indicator solution, mix and tube. Sterilize at 
121°C for 15 min and cool to form slopes with deep butts. 
7.  Glucose phosphate broth 
Peptone 5g 
Dipotassium hydrogen phosphate 5g 
Water 1 ltr 
Glucose 10% solution 50ml 
 Dissolve the peptone and phosphate and adjust the pH to 7.6. Filter dispense in 
5ml amounts and sterilize at 121°C for 15min. Sterilize the glucose solution by filtration 
and add 0.25ml to each tube. 
Methyl Red Reagent 
Methyl Red  l0mg 
Ethyl alcohol  30ml 
Distilled water  20ml 
Voges Proskauer Reagent 
Reagent A: Alpha naphthol  5g 
Ethyl alcohol  100ml 
Reagent B: Potassium hydroxide  40g 
Distilled water  100ml 
8. Peptone water fermentation test medium 
 To the basal medium of peptone water, add sterilised sugars of 1% indicator 
bromothymol blue with Durham's tube. Basal medium peptone water Sugar solutions: 
Sugar  1ml 
Dislilled water  100ml  
pH = 7.6. 
9.  Mannitol motility medium 
Agar       5g 
Peptone      lg 
Potassium nitrate     1g 
Mannitol       2g 
Phenol red indicator 
Distilled water      1000ml  
pH        7.2 
10.  Phenolphthalein diphosphate agar 
 Sterilize a 1% aqueous solution of sodium phenolphthalein diphosphate by 
filtration and store at 4°C 
 Add 10ml of this solution to 1000ml melted nutrient agar cooled to 50°C and 
pour plates 
 Grow the staphylococcus overnight at 37°C on the medium 
 Invert the plate and pour a few drops of ammonia solution SG 0.88 into the lid 
 Read as positive a culture whose colonies turn bright pink within a few minutes. 
The colour soon fades. 
11.  Potassium nitrate broth 
Potassium nitrate (KNO3) 0.2gm 
Peptone 5.0gm 
Distilled water 100ml 
The above ingredients were mixed and transferred into tubes in 5 ml 
amount and autoclaved. 
12. Phenyl alanine deaminase test 
Yeast Extract 3g 
Dl-Phenylalamine 2 g  
Disodium hydrogen phosphate l g  
Sodium Chloride 5 g  
Agar 12g 
Distilled water 1 lr 
PH 7.4 
Distributed in tubes and sterilized by autoclaving at 121° C for 1 5 
minutes, allowed to solidify as long slopes. 
13. Sugar fermentation medium 
Peptone 15g 
Andrade's indicator 10 ml 
Sugar to be tested 20g 
Water 1 litre 
Andrade's indicator is prepared from 0.5% aqueous acid fuchsin to 
which sufficient 1M sodium hydroxide has been added to turn the colour of the 
solution yellow. 
Dissolve the peptone and Andrade's indicator in 1 litre of water and add 
20g of the sugar; sugars to be tested generally include glucose, sucrose, lactose 
and maltose. Distribute 3ml amounts in standard test tubes containing an 
inverted Durham tube. Sterilize by steaming at 100 degree C for 30 min on 3 
consecutive days. 
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ANNEXURE-II 
PROFORMA 
 Name :        \IP no: 
 Age:  Sex:   Ward: 
 Occupation: 
 Address: 
 Presenting complaints: 
o Abdominal swelling 
o jaundice 
o High grade fever 
o Altered sensorium 
o Cough with expectoration 
o Burning  micturition 
o Hemoptysis: 
o  Abdominal pain: 
o  abdominal discomfort 
o  Leg swelling  
Past history: 
• Hepatitis 
• Known tuberculosis patient 
• Chronic steroid intake 
• Diabetes mellitus 
• Malignancy 
• Chemotherapy 
• Transplant recipient 
• HIV  
Personal history: 
• Alcohol intake: 
• Cigarette smoking: 
• Exposure to chemicals occupationally 
 Physical and General Examination : 
BP :      PR : 
CVS :      RS : 
P/A :      P/R  : 
Provisional Diagnosis: 
Laboratory Investigations : 
1. Complete haemogram . 
2. Liver function test 
3. Renal function test  
Serological investigations    
 HbsAg 
 ANTI-HCV        
 HIV 
Other Investigations 
Ultrasono gram: 
Chest X ray: 
CT  Abdomen : 
MICROBIOLOGICAL INVESTIGATION: 
 
Sample collected: 
         1.Ascitic fluid. 
         2. serum. 
         3. Blood sample. 
         4.urine. 
         5.sputum. 
         6. Wound swab 
Direct examination: 
Gram’s stain: 
Bacterial Culture (other samples) : 
 MAC 
 BAP 
 CAP 
Blood culture: 
 Inoculated onto BHI broth with subculture onto 
o MAC 
o BAP 
o CAP 
Isolate identified in the   sample: 
Antibacterial susceptibility pattern : 
Complement  component  C3 level: 
ANNEXURE –III 
CONSENT FORM 
STUDY TITLE: 
A Study on bacterial infections and their antimicrobial 
susceptibility pattern in Decompensated liver disease patients (DCLD) in a 
tertiary care hospital 
I……………………………………, hereby give consent to participate 
in the study conducted by Dr.J.RAJESWARI, Post graduate at Institute of 
Microbiology, Madras Medical College, Chennai and to use my personal 
clinical data and the result of investigations for the purpose of analysis and to 
study the nature of the disease, I also give consent to give my ascitic fluid / 
urine/ sputum/ wound swab/ blood for further investigations. I also learn that 
there is no additional risk in this study. I also give my consent for my 
investigator to publish the data in any forum or journal. 
 
Signature / Thumb impression of the patient / 
relative 
Place : 
Date : 
Patient Name & Address:  
 
Signature of the investigator 
S. No Patient's 
Age
Sex                  
Diagnosi
s
                 Sample CULTURE 
RESULT
Complememnt C3 level 
[mg/ml]
Alcohol Viral Cryptoge
ni
Blood OTHER SAMPLE Amik Genta Cef CS Cip Ofl Imi Pip/Taz Chlor Tetra Cot Clin Ery Pen Ceph Van NOR Nitr Amp Amox Cefoxiti
n
HLG
1 46 M DCLD y Ascitic fluid,Blood Klebsiella 
pneumoniae
Klebsiella pneumoniae
0.42
S S S S R S S S
2 35 M DCLD y Ascitic fluid,Blood No growth E.Coli  (ESBL)  0.16 S R R S S S S
3 50 M DCLD y Blood, Sputum Klebsiella 
pneumoniae
Normal throat 
commensal 1.92
S S S S S S S S
4 31 M DCLD Y URINE,Blood No growth Enterobacter cloaca 1.6 S S S S S S S S
5 30 M DCLD Y Blood, Ascitic fluid No growth No growth 0.44
6 47 M DCLD Y Sputum, Blood No growth E.Coli (ESBL) 0.2 S R R S R S S
7 34 M DCLD Y Ascitic fluid,Blood No growth No growth 0.4
8 67 M DCLD Y Ascitic fluid,Blood No growth E.Coli  (ESBL)  0.21 S S R S S S S
9 40 M DCLD Y Ascitic fluid,Blood No growth No growth 0.136
10 45 M DCLD Y Wound swab,Blood No growth Proteus vulgaris (ESBL)
0.206
S S R S R S S S
11 38 M DCLD Y Ascitic fluid,Blood No growth No growth 0.256
12 54 M DCLD Y Ascitic fluid,Blood No growth Proteus mirabilis 0.16 S S S S S S
13 54 M DCLD Y URINE,Blood No growth E.Coli 0.24 S S S S S S S S
14 34 M DCLD Y Ascitic fluid,Blood No growth No growth 0.56
15 38 M DCLD Y URINE,Blood No growth No growth 0.64
16 42 M DCLD Y URINE,Blood No growth Klebsiella oxytoca 
(ESBL) 0.4
S S R S R S S S R
17 48 M DCLD Y Sputum, Blood No growth Normal flora grown in 
culture 0.32
18 45 M DCLD y Y Ascitic fluid,Blood No growth Acinetobacter 0.16 S S S S S S S
19 36 M DCLD y Sputum, Blood No growth Klebsiella oxytoca 
(ESBL) 0.24
S S R S R S S S
20 47 M DCLD Y URINE,Blood No growth No growth 0.44
21 49 M DCLD y Blood, Ascitic fluid Streptococcal 
viridans
No growth
0.32
S S S S S R S
22 42 M DCLD y Blood, Urine Stapylococcus 
aureus (MRSA)
No growth 
0.4
S S R R R R R S R
23 45 M DCLD y Blood, Sputum No growth Normal throat 
commensal 2
24 52 M DCLD y Ascitic fluid,Blood No growth No growth 0.28
25 60 M DCLD y Wound swab,Blood No growth No growth 0.72
26 35 M DCLD Y Ascitic fluid,Blood No growth E.Coli 0.32 S S R R R S S
27 40 M DCLD y URINE,Blood No growth No growth 0.46
28 30 M DCLD y Sputum, Blood No growth Klebsiella oxytoca 0.32 R R R R R R R R
29 58 M DCLD y Ascitic fluid,Blood No growth No growth 0.48
30 44 M DCLD y URINE,Blood No growth Candida non albicans
0.38
31 40 M DCLD y Wound swab,Blood No growth Proteus vulgaris 0.24 R R R S S S S S
32 40 M DCLD y Blood, Ascitic fluid No growth No growth 0.28
33 70 F DCLD y Wound swab,Blood No growth Staphylococcus 
epidermidis(MS) 0.256
S S R S S S S S S
34 57 M DCLD y Wound swab,Blood No growth E.Coli (ESBL) 0.48 S S R S R S S
35 43 M DCLD y Blood, Urine Staphylococcus 
epidermidis 
(MSSA)
No growth
0.45
S S S R S S S R S
36 50 F DCLD Y Ascitic fluid,Blood No growth No growth 1.4
37 55 M DCLD y Blood, Sputum No growth Normal throat 
commensal 0.24
38 35 M DCLD Y Ascitic fluid,Blood No growth No growth 2
39 42 M DCLD y URINE,Blood No growth Klebsiella pneumoniae
0.38
S S S S S S S R S
40 35 M DCLD y Ascitic fluid,Blood No growth No growth 0.54
41 56 M DCLD y Blood, Urine No growth No growth 0.32
Causes of cirrhosis Antibiotic sensitivity 
S. No Patient's 
Age
Sex                  
Diagnosi
s
                 Sample CULTURE 
RESULT
Complememnt C3 level 
[mg/ml]
Alcohol Viral Cryptoge
ni
Blood OTHER SAMPLE Amik Genta Cef CS Cip Ofl Imi Pip/Taz Chlor Tetra Cot Clin Ery Pen Ceph Van NOR Nitr Amp Amox Cefoxiti
n
HLG
Causes of cirrhosis Antibiotic sensitivity 
42 43 M DCLD Y Ascitic fluid,Blood No growth No growth 0.52
43 40 M DCLD Y URINE,Blood No growth E.Coli 0.2 S S S S S S S S R
44 62 M DCLD Y URINE,Blood No growth E.Coli (ESBL) 0.32 S S R S S S R R R
45 39 M DCLD Y Ascitic fluid,Blood No growth No growth 0.48
46 50 M DCLD Y URINE,Blood No growth Klebsiella pneumoniae 
(ESBL) 0.24
S S R S S S S R S
47 48 M DCLD y Sputum, Blood No growth Pseudomonas 
aeruginosa 0.38
S S S S S S S R
48 42 M DCLD Y URINE,Blood No growth Klebsiella pneumoniae 
(ESBL) 0.38
S S R S S S S S R
49 50 M DCLD Y URINE,Blood No growth E.Coli 0.04 S R S S S S S R R
50 40 M DCLD Y URINE,Blood No growth Klebsiella oxytoca 
(ESBL) 0.36
S S R S S S S R R
51 46 M DCLD Y Sputum, Blood No growth Klebsiella pneumoniae
0.52
S S S S S S S S
52 35 M DCLD Y Blood, Ascitic fluid No growth No growth 0.47
53 58 M DCLD Y Y Ascitic fluid,Blood No growth Citrobacter koseri 0.15 S R S S S
54 43 M DCLD Y URINE,Blood No growth Candida non albicans
1.08
55 51 M DCLD Y Ascitic fluid,Blood No growth No growth 0.65
56 58 M DCLD Y Ascitic fluid,Blood No growth Klebsiella pneumoniae 
0.37
R R R R S S S R R
57 50 M DCLD Y Blood, Ascitic fluid Klebsiella 
pneumoniae
No growth
0.24
s S S S S S S S S
58 35 M DCLD Y Blood, Sputum No growth Normal throat 
commensal 0.25
59 35 M DCLD Y Blood, Wound swab No growth No growth
0.52
60 37 M DCLD y Blood, Urine Klebsiella 
pneumoniae  
(ESBL)
No growth
0.18
S R R S R S S S R
61 55 M DCLD y URINE,Blood No growth No growth 0.46
62 30 M DCLD Y Ascitic fluid,Blood No growth No growth 0.25
63 46 M DCLD y Wound swab,Blood No growth No growth 0.52
64 44 M DCLD y Blood, Ascitic fluid Klebsiella 
pneumoniae 
No growth
0.32
R R R R R S S R R S
65 50 M DCLD y Blood, Wound swab Stapylococcus 
aureus (MRSA)
No growth
0.14
S S R S S R R R R
66 42 M DCLD Y Blood, Sputum No growth Normal throat 
commensal 0.4
67 57 M DCLD y Blood, Urine Pseudomonas 
aeruginosa
No growth
1
S S S S S S S
68 59 M DCLD y Sputum, Blood No growth Klebsiella pneumoniae 
(ESBL) 0.24
R R R S R S S R
69 60 F DCLD y Ascitic fluid,Blood No growth Enterococcus faecalis
0.32
S R R S S S R
70 42 M DCLD Y URINE,Blood No growth Klebsiella oxytoca 
(ESBL) 0.2
R R R S R S S R R
71 42 M DCLD Y Ascitic fluid,Blood No growth No growth 0.12
72 46 M DCLD Y URINE,Blood No growth E.Coli (ESBL) 0.38 S R R S S S S S R
73 59 M DCLD Y Ascitic fluid,Blood No growth E.Coli 0.28 S S S S S S S
74 55 M DCLD Y URINE,Blood No growth Acinetobacter 
baumanii (ESBL) 0.38
R R R S S S S R S
75 53 M DCLD Y Sputum, Blood No growth Klebsiella 
pneumoniae(ESBL) 0.29
R R R S S S S R
76 40 M DCLD Y Ascitic fluid,Blood No growth No growth 0.33
S. No Patient's 
Age
Sex                  
Diagnosi
s
                 Sample CULTURE 
RESULT
Complememnt C3 level 
[mg/ml]
Alcohol Viral Cryptoge
ni
Blood OTHER SAMPLE Amik Genta Cef CS Cip Ofl Imi Pip/Taz Chlor Tetra Cot Clin Ery Pen Ceph Van NOR Nitr Amp Amox Cefoxiti
n
HLG
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77 39 M DCLD Y Sputum, Blood No growth Klebsiella oxytoca 0.4 S S S S S S S S
78 30 M DCLD Y Blood, Ascitic fluid No growth No growth 0.8
79 60 M DCLD Y Ascitic fluid,Blood No growth  Stapylococcus 
epidermidis(MS) 0.28
R S S S R S S S S
80 58 M DCLD y URINE,Blood No growth Candida non albicans
0.25
81 35 M DCLD y Ascitic fluid,Blood Pseudomonas 
aeruginosa 
Pseudomonas 
aeruginosa 0.16
R S R R R S S
82 40 M DCLD Y Sputum, Blood No growth Norrmal throat 
commensal 0.34
83 42 M DCLD Y URINE,Blood No growth E.Coli (ESBL) 0.34 S R R S R S R S R
84 40 M DCLD Y Ascitic fluid,Blood No growth No growth 0.56
85 30 M DCLD Y Ascitic fluid,Blood No growth Klebsiella oxytoca 0.32 S S S S S S S
86 78 M DCLD Y Sputum, Blood No growth Normal thoat 
commensal grown 0.36
87 36 M DCLD Y URINE,Blood No growth No growth 0.48
88 42 M DCLD Y URINE,Blood No growth Enterococcus faecalis
0.26
S S R R S R R
89 36 M DCLD Y Ascitic fluid,Blood No growth No growth
90 42 M DCLD Y Sputum, Blood No growth Pseudomonas 
aeruginosa (ESBL)
S S R S R S R S
91 40 M DCLD Y Blood, Wound swab Stapylococcus 
aureus (MSSA)
No growth S R S S S S S S S
92 37 M DCLD Y Blood, Sputum E.Coli Normal throat 
commensal
S S S S S S S S
93 60 M DCLD Y Blood,Urine Staphylococcus 
epidermidis 
(MSSA)
No growth S R S R S S S S S
94 54 M DCLD Y Blood, Ascitic fluid No growth No growth
95 43 M DCLD Y URINE,Blood No growth Klebsiella oxytoca 
(ESBL) 
R R R S R S S S S
96 40 M DCLD Y Ascitic fluid,Blood No growth No growth
97 61 M DCLD Y Blood, Ascitic fluid No growth No growth
98 57 M DCLD Y Blood, Wound swab No growth No growth
99 47 M DCLD Y Blood, Sputum Streptococcal 
viridans
Normal throat 
commensal
S S R R S S S
100 55 M DCLD Y Wound swab,Blood No growth Pseudomonas 
aeruginosa
S S S S S S S
101 37 M DCLD Y Ascitic fluid,Blood No growth No growth
102 39 M DCLD Y Sputum, Blood No growth Klebsiella oxytoca S R R R S S S S
103 54 M DCLD Y Ascitic fluid,Blood No growth Stapylococcus aureus 
(MRSA)
S R S S R S R S R
104 42 M DCLD Y Ascitic fluid,Blood No growth No growth R
105 30 M DCLD Y Ascitic fluid,Blood No growth No growth
106 78 M DCLD Y Blood, Urine No growth No growth
107 36 M DCLD Y Ascitic fluid,Blood No growth Klebsiella pneumoniae 
(ESBL) 
S S R S R S S
108 35 M DCLD Y Ascitic fluid,Blood No growth Stapylococcus aureus 
(MRSA)
S S S R S S R S R
109 57 M DCLD Y Wound swab,Blood No growth  Staphylococcus 
epidermidis(MS)
R R S S S R R S S
110 45 M DCLD Y URINE,Blood No growth No growth
111 30 M DCLD Y Ascitic fluid,Blood No growth No growth
112 45 M DCLD Y Ascitic fluid,Blood No growth No growth
113 35 M DCLD Y Ascitic fluid,Blood No growth E.coli (ESBL) S S R S R S S
S. No Patient's 
Age
Sex                  
Diagnosi
s
                 Sample CULTURE 
RESULT
Complememnt C3 level 
[mg/ml]
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114 47 M DCLD Y Sputum, Blood No growth Klebsiella oxytoca 
(ESBL)
R S R S R S S R
115 52 M DCLD Y Y Ascitic fluid,Blood No growth No growth
116 65 M DCLD Y Ascitic fluid,Blood No growth Stapylococcus aureus 
(MRSA)
S S S R R S R S R
117 54 M DCLD Y Blood, Ascitic fluid No growth No growth
118 45 M DCLD Y URINE,Blood No growth E.Coli (ESBL) S S R S R S S R S
119 51 M DCLD Y Blood, Wound swab Pseudmonas 
aeruginosa
No growth S S R R R S S
120 41 M DCLD Y Blood, Sputum No growth Normal throat 
commensal
121 56 M DCLD Y Blood, Urine No growth No growth
122 48 M DCLD Y Blood, Ascitic fluid No growth No growth
123 45 M DCLD Y Wound swab,Blood No growth Stapylococcus aureus 
(MRSA)
S R R S S S R R R
124 30 F DCLD Y Ascitic fluid,Blood No growth No growth
125 50 M DCLD Y Wound swab,Blood No growth Klebsiella pneumoniae 
(ESBL)
S R R S R S S S
126 40 M DCLD Y URINE,Blood No growth E.Coli R R R R R S R S R
127 34 M DCLD Y Wound swab,Blood No growth
128 59 M DCLD Y Sputum, Blood No growth Pseudomonas 
aeruginosa
S S S S S S S S
129 49 M DCLD Y URINE,Blood No growth Klebsiella oxytoca 
(ESBL)
S R R S S S S R S
130 42 M DCLD Y URINE,Blood No growth No growth
131 38 M DCLD Y URINE,Blood No growth Klebsiella oxytoca S S S S S S S R R
132 39 M DCLD Y Ascitic fluid,Blood No growth No growth
133 60 M DCLD Y Wound swab,Blood No growth Proteus vulgaris (ESBL) S S R S S S R S
134 57 M DCLD Y URINE,Blood No growth No growth
135 60 M DCLD Y Blood, Sputum No growth Normal throat 
commensal
136 39 M DCLD Y Y Ascitic fluid,Blood No growth Enterococcus faecalis S R R S R S S
137 46 M DCLD Y Ascitic fluid,Blood No growth E.Coli (ESBL) R R R S R S S
138 35 M DCLD Y URINE,Blood No growth No growth
139 30 M DCLD Y Blood, Wound swab E.Coli ,No growth S R R R R S S
140 49 M DCLD Y Ascitic fluid,Blood No growth Klesiella pneumoniae 
(ESBL)
S R R S S S R
141 43 M DCLD Y Sputum, Blood No growth Klebsiella oxytoca 
(ESBL)
S R R S S S S R
142 52 M DCLD Y Ascitic fluid,Blood No growth No growth
143 58 M DCLD Y Blood, Urine No growth No growth
144 38 M DCLD Y Ascitic fluid,Blood No growth Enterobacter spp 
(ESBL)
S R R S R
145 66 M DCLD Y Ascitic fluid,Blood No growth E.coli S S S S S S S S
146 56 F DCLD Y Wound swab,Blood No growth Stapylococcus aureus 
(MSSA)
S S R S S S R S S
147 40 M DCLD Y URINE,Blood No growth Acinetobacter Spp 
(ESBL)
S S R S R S S R S
148 60 M DCLD Y Blood, Ascitic fluid No growth No growth
149 47 M DCLD Y Sputum, Blood No growth Normal thoat 
commensal grown 
150 58 M DCLD Y URINE,Blood No growth No growth
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